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Chapter 1
Introduction
Sulfate esters are participating in a wide spectrum of biological reactions. They are
found in a number of organic compounds of the cell, like glycosaminoglycans (der-
matan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate) and sulfated
glycolipids (cerebroside sulfate), tyrosine-, serine-, and threonine-sulfate carrying
proteins[1] and sulfated hydroxysteroids (cholesterol sulfate, dehydroepiandros-
terone sulfate). Sulfate esters are synthesized by a class of enzymes known as sulfo-
transferases. Sulfotransferases catalyze the transfer of a sulfate (i.e, sulfonate, SO−3 )
group from an activated donor onto a hydroxyl or less frequently an aminogroup
of the acceptor molecule. The nucleotide analogue 3’ phosphoadenosine 5’ phos-
phosulfate (PAPS) invariably serves as the sulfate donor [2]. The sulfate esters are
hydrolyzed by enzymes belonging to the family of sulfate ester sulfohydrolases or
sulfatases. In this thesis, we take a comprehensive look at the sulfatases and their
activating enzyme(s).
Sulfatases cleave sulfate esters such as N and O-sulfate esters in biological
systems (Eq.1 and 2). It plays a key role in regulating the sulfation states that
determine the function of many physiological molecules.
R− SO−3 +H2O ⇒ R−OH +H+ + SO2−4 (1)
R−NHSO−3 +H2O ⇒ R−NH+3 + SO2−4 (2)
Sulfatase substrates range from small cytosolic steroids, such as estrogen sulfate, to
complex cell surface carbohydrates, such as the glycosaminoglycans. The trans-
formation of these molecules has been linked with important cellular functions
including hormone regulation, cellular degradation and modulation of signaling
pathways. Sulfatases have also been implicated in the onset of various patho-
physiological conditions including hormone-dependent cancers, lysosomal storage
disorders, developmental abnormalities and bacterial pathogenesis.
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1.1 Sulfatase family and Subcellular localization
The sulfatase family comprises a class of enzymes that is highly conserved
sequentially, structurally and mechanistically across eukaryotic and prokaryotic
species. The remarkable similarities shared by sulfatases include: 1) 20-60 %
sequence homology over the entire protein length, 2) a highly conserved N-
terminal region containing consensus sulfatase motifs [3, 4](Fig1.1). The extent
of sequence similarity and structural likeness suggests that they emerged long ago
from a commmon ancestral gene [5, 6]
Human sulfatases
(from genome):
Length
(residues)
Signal
peptide
Arylsulfatase A C T P S R A A L L T G R (Pos.69-80) 507 +
Arylsulfatase B C T P S R S Q L L T G R (Pos.91-102) 533 +
Arylsulfatase C C T P S R A A F M T G R (Pos.83-94) 583 +
Arylsulfatase D C T P S R A A F L T G R (Pos.89-100) 593 +
Arylsulfatase E C T P S R A A F L T G R (Pos.86-97) 589 +
Arylsulfatase F C S P S R S A F L T G R (Pos.79-90) 591 +
Arylsulfatase G C T P S R A A F L T G R (Pos.181-192) 688 ?
N-Acetylgalactosamine 6-sulfatase C S P S R A A L L T G R (Pos.79-90) 522 +
Nacetylglycosamine 6-sulfatase C C P S R A S I L T G K (Pos.91-102) 552 +
Iduronate sulfatase C A P S R V S F L T G R (Pos.84-95) 550 +
Sulfamidase C S P S R A S L L T G L (Pos.70-81) 502 +
Sulf 6 C S P S R A S L L T G R (Pos.84-95) 525 +
C C P S R S S M L T G K (Pos.87-98) 871 +
C C P S R S S I L T G K (Pos.88-99) 870 +
Sulf 3 C C P S R A A M W S G L (Pos.70-81) 526 +
Sulf 4 C T P S R S Q F I T G K (Pos.96-107) 573 +
Sulf 5 C T P S R S Q L L T G R (Pos.93-104) 569 +
Lower eukaryotic sulfatases: 
Coturnix coturnix(Qsulf1) C C P S R S S M L T G K (Pos.87-98) 869 +
Hemicentrotus pulcherrimus C T P S R S A I M T G R (Pos.100-111) 551 +
Strongylocentrotus purpuratis C T P S R S A I V T G R (Pos.115-126) 567 +
Heliocidaris erythrogramma C T P S R S A I M T G R (Pos.106-117) 559 +
Volvox carteri C C P S R T N L W R G Q (Pos.72-86) 649 +
Chlamydomonas reinhardtii C C P S R T N L W R G Q (Pos.73-84) 646 +
Neurospora crassa C C P A R V S L W T G K (Pos.89-100) 639 +
Sulf
Sulf 2
1
Figure 1.1. Partial alignment of sulfatase protein family. This consensus sequence is important
for directing the first amino acid residue to the catalytically active FGly. Highly conserved residues
are shown in gray.
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The human genome predicts 17 sulfatases of which 11 have been characterized
and found to show distinct sulfatase activities and subcellular localization (1.1). A
subgroup of seven human sulfatases were termed arylsulfatases due to their ability
to cleave synthetic chromogenic or fluorogenic substrates that are applied in the
enzyme assays and histochemistry. At least eight human sulfatases were localized
in the lysosomes, where they catalyse the degradation of glycosaminoglycans
and sulfolipids. The arylsulfatase C (Steroid Sulfatase) is an integral membrane
protein of the endoplasmic reticulum and the plasma membrane. It is involved
in cholesterol and steroid hormone metabolism. Arylsulfatase D, E, F and
G are non lysosomal proteins that have been localized to the endoplasmic
reticulum(arylsulfatase D,F and G) and Golgi apparatus(arylsulfatase E) [4, 7].The
physiological roles of arylsulfatase D,E,F and G are still to be determined,
although there are indications that arylsulfatase E is possibly involved in Vitamin K
metabolism [8].
The newly discovered sulfatases Sulf1 and Sulf2 are localized at the cell
surface[7].Sulf1 has been involved in the modification of the sulfation of
glycosaminoglycans (GAGs) which dictate developmental cell signaling and
patterning processes. QSulf1 (Quail Sulfatase1) regulates the Wnt signaling
by cleaving the 6-O sulfate from heparan sulfate proteoglycan which releases
Wnt. The ”Catch and Present” model was suggested for the regulation of Wnt
signaling by QSulf1[9]. In this model, desulfation by QSulf1 is proposed to
stimulate a shift from a high affinity heparan sulfate-Wnt complex (the catch
phase) to a low affinity heparan sulfate-Wnt complex, which allows interaction
of Wnt with frizzled receptors (the present phase) to initate the Wnt signaling
cascade. Desulfation of heparan sulfate proteoglycans by HSulf1 influences many
other signaling pathways including Epidermal Growth Factor (EGF) and Fibroblast
Growth Factor (FGF) mediated signaling [10]. In addition, Sulfs have been
implicated in pathophysiological conditions including tumor onset and progression
[11].
1.2 Single sulfatase deficiencies
The biological importance of human sulfatases is highlighted by the manifesta-
tion of eight known inherited metabolic disorders. They are associated with im-
paired desulfation of specific substrate metabolites and with their lysosomal stor-
age (Table1.2). For example, arylsulfatase A is required to catalyze the first
step in the degradation pathway of galactosyl-3-sulfate ceramide (Sulfatide), a
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Table 1.1. Substrates and subcellular location of human sulfatases
Sulfatase Abbr Physiological Subcellular
substrate location
arylsulfatase A ARSA sulfatide lysosome
arylsulfatase B ARSB dermatan sulfate lysosome
chondroitin sulfate
arylsulfatase C ARSC steroid sulfates ER
arylsulfatase D ARSD unknown ER
arylsulfatase E ARSE unknown Golgi network
arylsulfatase F ARSF unknown ER
arylsulfatase G ARSG unknown ER
galactosamine-6-sulfatase GalN6S chondroitin sulfate lysosome
keratan sulfate
glucosamine-3-sulfatase GlcN3S heparan sulfate lysosome
glucosamine-6-sulfatase GlcN6S heparan sulfate lysosome
keratan sulfate
glucuronate-2-sulfatase GlcA2S heparan sulfate lysosome
heparan-N-sulfatase GlcNS heparan sulfate lysosome
iduronate-2-sulfatase IdoA2S heparan sulfate lysosome
IdoA2S dermatan sulfate
endo sulfatase 1 Sulf1 heparan sulfate cell surface
endo sulfatase 2 Sulf2 heparan sulfate cell surface
major sphingolipid of myelin[12]. Deficiency of this sulfatase is the cause of
Metachromatic Leukodystophy (MLD), a lysosomal storage disorder that leads to
severe neurological symptoms because of extensive demyelination in the central
and peripheral nervous system. Arylsulfatase B is involved in degradative pathways
of dermatan sulfate and chondroitin 4-sulfate [5]. These glycosaminoglycans are
constituents of proteoglycans existing in the extracellular matrix. Deficiency of
arylsulfatase B leads to Mucopolysaccaridosis VI, a lysosomal storage disorder
with a variety of clinical phenotypes such as dwarfism, skeletal abnormalities,
cloudy cornea and heart failure [5]. Deficiency of arylsulfatase C leads to X-
linked ichthyosis, a relatively mild disease of the skin with increased levels of
cholesterol sulfate in the stratum corneum [13]. These distinct single sulfatase
deficiencies emphasise the high substrate specificity of the sulfatases and their
limited functional redundancy. The resulting phenotypes range from extremely
severe and life threatening with early death to reduced life expectancy. The
deficiency of sulfatases in case of each syndrome is caused by different genetic
defects. For instance, one of the most common mutations associated with a mild
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form of MLD is a substitution of proline 426 by leucine in arylsulfatase A (ASA). The
resulting deficiency of ASA is caused by its instability in the lysosomes. It was shown
that the instability of the mutated enzyme, caused by its defective oligomerization in
the lysosmes, drastically increases the vulnerability of the enzyme to degradation by
lysosomal cysteine proteases [14]. Point mutations of the corresponding sulfatase
genes are also the cause of many other sulfatase deficiencies, among them various
mucopolysaccaridoses (MPS).
Table 1.2. Inherited disorders resulting from deficiency in a single sulfatase
Subcellular location Sulfatase Genetic disorder
lysosome ARSA metachromatic leukodystrophy (MLD)
IdoAS Hunter’s disease (MPS II)
GlcNS Sanfilippo A (MPS IIIA)
GlcN6S Sanfilippo (MPS IIID)
GalN6S Morquio A (MPS IVA)
ARSB Maroteaux-Lamy (MPS VI)
ER ARSC X-linked ichthyosis (XLI)
Golgi ARSE chondrodysplasia punctata (CDPX)
1.3 Multiple sulfatase deficiency and Cα-formylglycine
In addition to single sulfatase deficiencies, a rare autosomal recessive disorder
called Multilpe Sulfatase Deficiency (MSD) is known, in which the activities of
all known sulfatases are severely decreased. Austin described the first case of
MSD in two siblings in 1963 and 1965. Since then a number of MSD patients
have been identified [12]. The clinical phenotype of MSD combines features
characteristic of single sulfatase deficiencies, such as rapid neurologic deterioration
and developmental delay.
Single sulfatase deficiency syndromes are caused by mutations in the correspond-
ing sulfatase genes. In case of each syndrome the activity of only one sulfatase
is decreased, all the other sulfatases are active within the normal range. On the
contrary, the activity of all the sulfatases are dramatically reduced in MSD patients,
this finding has led to the proposal that there must be a common reason for the
deficiency of all sulfatases. Studies in cultured cells from MSD patients have
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shown that synthesis of sulfatase polypeptides is normal but their catalytic activity
is severely diminished and for some of the sulfatase polypeptides their stability as
well [15, 16]. Expression of sulfatase cDNAs in MSD fibroblasts yielded sulfatase
polypeptides with a severely reduced activity [17]. Therefore it was proposed that
sulfatases require co- or post- translational modification that is missing in case of
MSD. By Mass spectrometric analysis of the sulfatase polypeptides (ASA and ASB)
synthesized in MSD fibroblasts revealed that they lack a Cα-formylglycine (FGly; 2-
amino-3-oxopropionic acid) residue and contain a cysteine instead, as predicted by
the cDNA [18]. The FGly residue is found at a position where the cDNA sequences
of all known eukaryotic sulfatases predict a cysteine within a highly conserved
sequence. This sequence of 12 amino acids is shown in Fig1.1. Later the presence of
FGly was shown also for lower eukaryotic [19] and prokaryotic [20, 21] sulfatases.
This demonstrates that the FGly residue is conserved in prokaryotic and eukaryotic
members of the sulfatase family and can be generated by oxidation of either a
cysteine (eukaryotes and prokaryotes) or, a serine residue (prokaryotes only) as
will be explained below.
1.3.1 Role of Formylglycine in sulfate ester hydrolysis
The crystal structures of human sulfatases ASA and and arylsulfatase B (ASB) have
been solved at 2.1 A˚and 2.5 A˚, respectively. The FGly residue was shown to be
located in the active site cavity (Fig1.2) representing part of metal binding site with
an octahedrally coordinated metal ion [22, 23]. The 3-D structure of the bacterial
sulfatase from Pseudomonas aeruginosa (PAS), resolved at 1.3 A˚, established the
metal ion in the active site as a Ca2+[24]. The structures of pro- and eukaryotic
active sites of sulfatases are identical within the error limits and show topographic
similarity to that of alkaline phosphatase. The side chain of FGly is superimposable
to that of the catalytically essential serine 102 in the alkaline phosphatase active
center [22].
Structural and enzymatic studies of ASA mutants, in which the cysteine was
replaced by a serine or alanine [25, 14] and the recent solution of the X-ray
structure of PAS [24] provided insight into the actual mechanism of sulfate ester
hydrolysis. The electron density map of the FGly side chain showed the presence
of two hydroxyl groups bonded to Cβ in FGly 51, the key catalytic site chain in
PAS, corresponding to FGly 69 in ASA and FGly 91 in ASB. Thus, the FGly residue
in the active enzyme is present as a FGly-hydrate (Fig1.3). One of the geminal
hydroxyl groups of the aldehyde hydrate serves as an acceptor for sulfate leading
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Figure 1.2. Active centre of human arylsulfatase A [14, 24]. The sulfate group of the substrate
is positioned in the active center and coordinated by lysine 123, serine150, histidine 229, lysine
302, a water molecule (W) and a Ca2+ ion. The nucleophilic attack on the sulfur atom by one
of the hydroxyl groups of FGly69-hydrate (distance 2.5 A) is facilitated by deprotonation of this
hydroxyl group by aspartate.
to the formation of a covalently sulfated enzyme intermediate. The function of this
hydroxyl group is similar to that of Ser 102 in alkaline phosphatase. The second
hydroxyl group of the aldehyde hydrate is proposed to induce an intramolecular re-
arrangement leading to elimination of the sulfate and regeneration of the aldehyde
group (Fig1.3).
After substrate desulfation, the alcohol is released and diffuses out of the
catalytic pocket. The sulfate is now covalently bound to the enzyme and additionally
coordinated to the calcium atom through two of its oxygen atoms. The C-O
bond in the FGly-sulfate ester is polarized through all the contacts of the sulfate
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Figure 1.3. Scheme of the proposed catalytic mechanism for sulfate ester hydrolysis [24].
Sulfate ester cleavage is initiated by formation of an aldehyde hydrate at the catalytic FGly
residue (I). Neucleophilic attack of the sulfate group by one of the hydroxyls of the aldehyde
hydrate leads to substitution of the alcohol (II). The sulfate group is then released from the
sulfated enzyme intermediate by an elimination reaction cleaving a C-O bond and regenerating
the aldehyde (III).
group to positively charged residues, favoring its elimination. The final step of
the reaction is the elimination of sulfate and regeneration of the aldehyde. The
aldehyde hydrate is regenerated by addition of a water molecule and is stabilized
by hydrogen bonds to histidine, arginine and the calcium atom. The mechanism,
as described, is based on the structural analyses of sulfatases and their substrate
complexes [23, 22, 14] and was also confirmed by kinetic studies of numerous
active site mutants [25, 26, 27]. The ASA-C69S and the corresponding ASB-C91S
mutants allowed to trap the sulfated FGly intemediate (Fig.1.4C). The sulfate could
no longer be eliminated from this intermediate, since the second hydroxyl group
was absent in these mutants [25]. The stuctural similarity of sulfatases and in
particular of their active site regions, strongly suggests that the proposed catalytic
mechanism is common for all sulfatases. The key function of the FGly residue in
this mechanism explains the critical role of the posttranslational generation of this
residue in the biogenesis of enzymatically active sulfatases.
1.3.2 Formylglycine modification motif
In experiments with in vitro synthesized ASA fragments it was shown that a se-
quence of 16 amino acid residues, encompassing positions -4 to +11 with respect
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to the cysteine to be modified (Fig.5), is essential and sufficient for the formation
of FGly [28], . Formation of FGly was observed with the same efficiency as that
of the control after transferring these 16 residues to a heterologous protein [29].
Analysis of different deletion- and substitution- mutants of ASA could show that
a sequence motif consisting of 12 consecutive residues starting with the cysteine
to be modified is nesessary to reach optimal FGly formation [29]. This sequence
consists of an essential core motif CxPxR and an auxiliary motif xxxL/MTGR/K/L.
Apart from cysteine, the key residues of the core motif are proline and arginine in
positions +2 and +4, respectively, which can be found in all known and putative
members of the sulfatase family. The auxiliary motif (position +5 to +11 after
cysteine that is to be modified) is playing a supporting but not an essential role
in FGly formation. Even complete substitution of the highly conserved amino acid
residues LTGR (Fig.1.5) by an AAAA-tetrapeptide led only to 50% reduction of FGly
formation [29]. It is proposed that this sequence of seven amino acid residues
facilitates presentation of the core motif to the modifying enzyme.
Figure 1.4. A short linear sequence determines the FGly formation [29]. The 16 mer sequence
of the human Arylsulfatase A is essential and sufficient for the modification of Cys69. Inhibition
of FGly formation after substitution of each single amino acid residue by alanine or glycine is
given in the upper row in numbers and indicated by different intensity of grey tones. In the lower
row, intensity of grey tones and percent values indicate the conservation level of the amino acid
residues among eukaryotic sulfatases. Comparison of the two rows demonstrate that all three
residues, C69, P71, R73, which are essential for FGly formation are 100% conserved among all
eukaryotic sulfatases.
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1.3.3 Formation of formylglycine in the endoplasmic reticulum
The cysteine residue encoded in the sulfatase gene, is incorporated into the nascent
sulfatase polypeptide chain during translation [28]. The cysteine is converted to
FGly during or shortly after protein translocation into the endoplasmic reticulum
(Fig1.3), as could be shown in an in vitro translation/translocation system compris-
ing import competent dog pancreas microsomes [28, 30]. It was shown that, in an
arrested translocation intermediate, the cysteine 69 of ASA was accessible inside
the microsomes. However, FGly formation was observed only after releasing the
nascent chain from the ribosome by puromycin [28]. Thus, FGly formation occurs
after or at a later stage of cotranslational protein translocation.
Figure 1.5. Conversion of the cysteine to a FGly residue in sulfatases occurs in the endoplasmic
reticulum. Early translocation intermediate (Stage 1) retaining the signal peptide (open box) still
carry the conserved cysteine residue. Completion of translocation (Stage 2) is associated with
cleavage of the signal peptide and conversion of the conserved cysteine (red) to FGly (blue). The
modified sulfatase polypeptides are supposed to complete folding in the endoplasmic reticulum
(Stage 3)[28].
In a recent study of in vitro FGly formation [31] it was investigated whether
the components of the FGly-generating machinery are part of the ER membrane or
the ER lumen or both. The dog pancreas microsomes were treated with increasing
detergent concentrations and separated into supernatant and pellet fractions by
centrifugation. Increasing concentrations of the detergent solubilized increasing
amounts of FGly-generating activity that was recovered in the supernatant fraction.
Under conditions that selectively extract the luminal components but leave mem-
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brane components in the pellet fraction, almost 100 percentage of FGly generating
activity was recovered in the supernatant and virtualy no activity remained in
the pellet fraction. Thus, the FGly modifying machinery is part of the soluble
components of the ER lumen referred to as reticuloplasm. In the same study it
was shown that in vitro formation of FGly by reticuloplasm does not depend on the
presence of the signal peptide sequence in the sulfatase substrate. Furthermore, the
FGly-generating enzyme was characterised with respect to some basic biochemical
properties such as pH optimum, which was unexpectedly high (pH 10-10.5). Kinet-
ically controlled conditions were established for assaying FGly formation in vitro.
The FGly forming activity showed typical enzymatic properties with a characteristic
temperature dependence (activation energy 61 kJ/mol) and sensitivity to inhibitory
peptides [31]. Reticuloplasm as a source for the FGly-generating enzyme and
the in vitro assay for detection of its activity are the basis for the functional and
chromatographic characterisation of the so far unknown modifying protein on the
way to its eventual identification.
1.4 FGly generating machinery in prokaryotes
Mammalian sulfatases are involved in the turnover of endogenous sulfated sub-
strates [32]. On the other hand, sulfatases of lower eukaryotes, like algae or fungi
and of bacteria, are expressed under conditions of sulfur starvation and function in
sulfate scavenging from exogenous substrates[33]. Due to conservation of the FGly
modification motif, most of the sulfatases encoded in various bacterial and archaea
bacterial genomes are predicted also to undergo FGly modification by oxidation
of cysteine or serine. This was shown experimentally for the arylsulfatase from
Pseudomonas aeruginosa (PAS) and Methanosarcina mazei sulfatase (MMS), two
members of the cysteine-type sulfatases. Even after strong overexpression in E. coli
PAS was quantitatively converted to the active FGly-bearing enzyme [21]. Thus,
the E. coli cytosol must contain the FGly modifying machinery. This machinery
is expressed even under excessive inorganic sulfate supply conditions and thus is
independent of the sulfur status of the cell, in contrast to expression of the sulfatase
structural genes, as shown for P.aeruginosa and K.pneumoniae [34, 35, 33]
The other well characterised bacterial sulfatase, the arysulfatase of K.pneumoniae,
is a serine- type sulfatase that carries FGly residue generated by oxidation of a serine
rather than a cysteine [20]. In contrast to the cytosolic cysteine-type sulfatases,
serine-type sulfatases are located in the periplasm [35, 36]. The key FGly motif
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(SXPXR) and also the auxiliary downstream element (LTG) are conserved in
serine-type sulfatases [29].
Despite these similarities, bacteria have two different pathways for FGly gener-
ation either from cysteine or serine. This is indicated by two observations: first,
substitution of the cysteine to be modified in Pseudomonas sulfatase by serine
totally blocks FGly formation [30]; second, expression of an active, FGly containing
Klebsiella sulfatase in E. coli essentially requires coexpression of the Klebsiella atsB
gene [37], while the genomic background of E. coli is sufficient for expressing an
active and modified Pseudomonas sulfatase. It was shown recently, that AtsB, which
is a iron-sulfur protein, is located in the cytosol and is interacting directly with
the serine-type FGly modification motif, which allows to consider the possibility
that AtsB itself is the oxidising enzyme converting serine to FGly [38]. Some iron
sulfur proteins related to AtsB were shown to have enzymatic redox functions by
generating radical species by reductive cleavage of S-adenosylmethionine (SAM)
through an unusual FeS center that is also present in AtsB [39, 40]. A possible
reaction sequence for AtsB-mediated FGly formation is outlined in Scheme.1
Transfer of an electron from the reduced FeS center to S-adenosylmethionine leads
to its reductive cleavage (step 1). The generated deoxyadenosyl radical abstracts
a hydrogen atom from the substrate, i.e. the Ser72 side chain, under formation of
deoxyadenosine and a substrate radical (step 2). The single electron of this radical
is then accepted by the FeS center, leading to its re-reduction, under formation of
FGly (step 3).
Scheme 1: Proposed mechanism for AtsB-mediated FGly-formation [38]
(1)[FeS]red + AdoMet
+ ⇒ [FeS]ox +Methionine+ Adoo
(2)Adoo +Gly − CH2OH ⇒ AdoH +Gly − [CHOH]o
(3)Gly − [CHOH]o + [FeS]ox ⇒ [FeS]red +Gly − CHO +H+
where, AdoMet+ = S-adenosylmethionine
Adoo = 5’-deoxyadenosyl radical
AdoH = 5’-deoxyadenosine
Gly-CH2OH = Serine
Gly-CHO = FGly
As FGly formation from a serine is most likely a single enzymatic reaction, AtsB
may suffice for FGly formation in serine-type sulfatases. On the contrary, the
cysteine-modifying enzyme could not be identified to date in bacteria. A transposon-
mutagenesis approach failed (in E. coli), indicating that the cysteine-modifying
system is either redundant or essential, i.e. required for other functions apart from
FGly- modification of sulfatases.
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1.5 Purification and identification of the mammalian
Cα-formylglycine generating enzyme
1.5.1 In vitro assay for FGly formation
Based on the information that translation of a 16 mer ASA sequence in a
heterologous polypeptide backround and its translocation into the endoplasmic
reticulum allows the generation of FGly, an in vitro assay for the FGly formation
was established. In this assay a detergent solubilized extract from bovine pancreas
microsomes served as a source of the modifying enzyme. As substrate (35S)
methionine labeled sulfatase polypeptide was used that was translated in vitro by
an mRNA programmed reticulocyte lysate. The polypeptides were added to the
assay mixture as ribosome-associated nascent chain complexes. The quantification
of the product included tryptic digestion, separation of the peptides by RP-HPLC,
and identification and quantification of the 35S-labeled FGly containing tryptic
peptide by a combination of chemical derivatization to hydrazones, RP-HPLC
separation , and liquid scintillation counting [31]. For monitoring the enzyme
activity during purification, this procedure was tedious to carry out. A new assay
based on a peptidic substrate and matrix-assisted laser desorption/ionisation time-
of-flight (MALDI-TOF) mass spectrometry was developed.
Previously it was shown that the 16-mer peptide corresponding to ASA residues
65-80 and containing the sequence motif required for FGly formation inhibited the
FGE activity in the in vitro assay [31]. This suggested that peptides such as ASA 65-
80 may serve as substrate for FGE. Thus a 23-mer peptide p23 which corresponds
to ASA residues 60-80 was synthesized. Incubation of P23 with extracts from
microsomes of bovine pancreas or bovine testis converted up to 95% of the peptide
into the FGly containing derivative (Fig1.6). Under standard conditions, the FGly
formation was proportional to the amount of enzyme and time of incubation as long
as less than 50% of the substrate was consumed and the incubation period did not
exceed 24hr. The KM for P23 was 13nM[41].
1.5.2 Purification of FGE
FGE was purified from the soluble fraction of bovine testis microsomes by a four-
step chromatography. The first two steps were chromatography on a MonoQ anion
exchanger and on concanavalin A-Sepharose. At pH8, the FGE activity bound
to MonoQ and was eluted at 50-165mM NaCl. When this fraction was mixed
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Figure 1.6. FGly Modification of P23. 6 pmol of P23 were incubated under standard
conditions for 10min at 37oC in the absence (top) or presence (bottom) of 1µl of microsomal
extract. The samples were prepared for MALDI-TOF mass spectrometry (see Materials and
methods). The monoisotopic masses MH+ of P23 (2526.28) and its FGly derivative (2508.29)
are indicated.
with concanavalin A-Sepharose, FGE was bound and eluted with 0.5 M α-methyl
mannoside. The two final purification steps were chromatography on affinity
matrices derivatized with 16-mer peptides. The first affinity matrix was Affigel 10
substituted with a variant of the ASA65-80 peptide, in which three residues critical
for FGly formation, Cys-69, Pro-71, and Arg-73, were scrambled (scrambled peptide
PVSLPTRSCAALLTGR). This peptide did not inhibit FGE activity when added at
10 µM concentration to the in vitro assay and when immobilized to Affigel 10,
did not retain FGE activity. Chromatography on the scrambled peptide affinity
matrix removed peptide binding proteins including chaperones of the endoplasmic
reticulum. The second affinity matrix was Affigel 10 substituted with a variant
of the ASA 65-80, in which the Cys-69 was replaced by a serine (Ser-69 peptide
PVSLSTPSRAALLTGR). The FGE activity could be eluted with either 2 M KSCN or 25
µM Ser-69 peptide. Prior to activity determination, the KSCN or Ser-69 peptide had
to be removed by dialysis. The substitution of Cys-69 by serine was crucial for the
elution of active FGE. Affigel 10 substituted with the wild-type ASA65-80 peptide
bound FGE efficiently. However, nearly no activity could be recovered in eluates
with chaotropic salts (KSCN, MgCl2), peptides (ASA65-80, or Ser-69 peptide), or
buffers with low or high pH. In Figure 1.6 the polypeptide pattern of the starting
material and of the active fractions obtained after the four chromatographic steps of
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Figure 1.7. Purification of FGE from Bovine Testis (Dierks et al., 2003)
Aliquots of the soluble extract from microsomes (lane 1), of the pooled fractions after
chromatography on MonoQ (lane 2), concanavalin A-Sepharose (lane 3), and scrambled peptide-
Affigel 10 (lane 4) were separated by SDS-PAGE. The entire material eluted from Ser-69 peptide-
Affigel 10 was concentrated and loaded in lane 5. Molecular weight standards are shown
a typical purification is shown. In the final fraction, 5% of the starting FGE activity
and 0.0006% of the starting protein were recovered (8333-fold purification).
1.5.3 Identification of FGE gene
Mass finger print analysis revealed that the 39.5 and 41.5 kDa polypeptides (see
Figure 1.7, lane 5) were encoded by a single gene called SUMF1. The SUMF1 gene
encoding human FGE is located on chromosome 3p26. Orthologous genes were
found in mouse (87% identity), rat (94% identity), Drosophila melanogaster (48%
identity), Anopheles gambiae (47% identity), and Fugu rubripes (63% identity).
Orthologous EST sequences were found for a number of other species too[42].
The genomes of S. cerevisiae and C. elegans lack SUMF1 homologs. In prokaryotes,
13 orthologs of the SUMF1 gene were found. Sequence comparison analysis of
human FGE suggested that FGE comprises 374 aminoacids including a cleavable
endoplasmic reticulum(ER) signal sequence. It is composed of three distinct sub-
domains [42], the N-terminal subdomain (residues 91-154) has a potential N-
glycosylation site at 141 which is conserved in other orthologs. The middle part
of FGE (residues 179-308) is represented by a tryptophan rich subdomain. The C-
terminal subdomain (residues 327-366) has the most conserved sequence within the
16 Chapter1. Introduction
FGE family. Among 40 residues of the subdomain four residues are fully conserved.
Three of these cysteines are also conserved in the prokaryotic FGE orthologs.
1.5.4 Expression and subcellular localization of FGE
The SUMF1 expression level is highest in pancreas and kidney and lowest in brain.
Transient expression of tagged and un-tagged FGE increased the FGE activity 1.6-
to 3.9-fold. Stable expression of FGE in PT67 cells increased the activity of FGE
about 100 fold [41]. Indirect immunofluoresence showed the colocalization of the
variously tagged forms of FGE with protein disulfide isomerase, a lumenal protein
of the endoplasmic reticulum in BHK21, CHO and HT1080 cells [41].
1.5.5 Mutation in SUMF1 causes MSD
MSD is caused by a deficiency to generate FGly residues in sulfatases [18]. It
was shown that mutations in the SUMF1 gene are the cause of multiple sulfatase
deficiency. So far 22 mutations of SUMF1 gene were described in 20 different
patients [41, 43]. Interestingly, seven mutations appear to be clustered in the C-
terminal subdomain of the protein, suggesting that this subdomain is critical for
SUMF1 activity. Five other mutaions are located in the tryptophan-rich subdomain
and one muataion is in the N-terminal subdomain. In addition, two mutations
of the first methionine and one located within the signal peptide were also found
[43]. For the three MSD-cell lines, it was shown that transduction of the FGE
encoding cDNA partially or fully restores the sulfatase activities. On the contrary,
transduction of the FGE encoding cDNA carrying one of the mutations observed
in MSD patients did not restore sulfatase activities [41]. MSD is both clinically and
biochemically heterogenous. Biochemically it is characteristic that a residual activity
of sulfatases is detected, which in cultured skin fibroblasts is generally below 10%
of controls [44, 45]. However, in some MSD cell lines, the activity of selected
sulfatases can reach the normal range [46]. Furthermore the residual activity is
subject to variations, depending on the cell culture conditions and unknown factors
[47, 48, 49, 50]. Biochemically MSD has been classified into two groups [50, 15].
In group I, the residual activity of sulfatases is below 15%, including that of ASB. In
group II, the residual activity of sulfatases is higher and particularly that of ASB may
reach values of up to 50-100% of control. The phenotypic heterogeneity suggests
that the different mutations in MSD patients are associated with different residual
activities of FGE [41].
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1.6 Aim
1.6.1 Characterization of pFGE, the paralog of FGE
The SUMF1 gene is conserved among pro- and eukaryotes [42]. In the genome of
deuterostomia, including vertebrates and echinodermata, a paralog of the SUMF1
gene, designated as SUMF2 is found [41, 51, 43]. Gene duplication of a common
SUMF ancestor gene obviously has occurred at the level of a single exon gene after
the evolution of insects and before that of deuterostomia. A high degree of sequence
similarity was observed along the entire length of SUMF1 and SUMF2 protein
sequences, with the exception of the hydrophobic N-terminal region. Therefore,
SUMF2 encoded protein was termed paralog of FGE (pFGE). Among the family of
SUMF2 encoded pFGE, the identity is much higher than to the SUMF1 encoded FGE
of the same species. For example, the identity between human and mouse pFGE
is 86%, while the identity with the corresponding FGE is 47%-49%. pFGE shares
the subdomain structure with FGE. In subdomain III, however, they lack two of the
three cysteines conserved among pro- and eukaryotic FGEs [41]. The human SUMF2
gene is located on chromosome 7q11. The human pFGE shares 47.1% sequence
identity and 62.1% similarity with human FGE (Fig1.8). The function of the paralog
FGE is unknown. Cotransfection of SUMF2 with sulfatase cDNAs such as those of
Figure 1.8. Human FGE and paralog FGE
arylsulfatase A, C, or E enhanced moderately, but consistently, the catalytic activity
of the sulfatases, suggesting that pFGE has some FGly -generating activity[51]. So
far, no mutations in the the SUMF2 gene have been found in multiple sulfatase
deficiency patients. In this thesis we have began to analyze the expression of
SUMF2, structural and functional properties of recombinant and endogenous pFGE.
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We have also examined the interaction of pFGE with sulfatases and determined the
modifying activity of pFGE on sulfatases.
1.6.2 Effect of FGE on sulfatases activity
Normally, the necessary amount of FGE required to modify sulfatases is constitu-
tively expressed in the cell. However, FGE is limiting to modify the recombinant
sulfatase which is excessively expressed[52, 18]. Furthermore, the recombinant
catalytically active sulfatases are needed for enzyme replacement therapy of pa-
tients suffering from the deficiency of lysosomal sulfatase, e.g., of arylsulfatase B
in Maroteaux-Lamy disease, Iduronate sulfatase in Hunter disease, and galactose
6-/N-acetylgalactosamine 6-sulfatase in Morquio A disease (for review see Neufeld
and Muenzer, 2001). In the present study, we have examined the utility of FGE
for expression of functional sulfatases. And we also investigated the interaction
between FGE and sulfatases.
Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Laboratory equipment
Analytic balances type 1602 MP and 1265 MP Sartorius, Goettingen
Analytical and preparative HPLC:
SMART-system with the following columns: Amersham Biosciences
Gel filtration columns:
Fast Desalting PC 3.2/10 (3.2 x 100 mm) Amersham Biosciences
Superdex 200 PC 3.2/30 (2.4ml) Amersham Biosciences
Anion exchange columns:
MonoQ PC 1.6/5 (0.1ml) Amersham Biosciences
MonoQ HR 10/10 (8ml) Amersham Biosciences
Reversed Phase columns:
Aquapore RP-300 (C8, 2.1 x 220 mm)
µPeak C2/C18 PC 3.2/3 (C2/C18, 2.1 x 30 mm) Amersham Biosciences
UV-detectors for SMART-system:
µPeak Detector Amersham Biosciences
UV-Detector for Vision Workstation:
FLUOR-305 PerSeptive Biosystems
Intelligent Dark Box II, Las-1000+ Fuji, Japan
Ice machine Ziegra, Isernhagen
Centrifuges:
Eppendorf centrifuge Type 5415C and 5402 Eppendorf, Hamburg
Table ultracentrifuge TL-100 Beckmann, Mu¨nchen
Ulracentrifuge L8-70M Beckmann, Mu¨nchen
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Cold Centrifuge J-21C and J2-MC Beckmann, Mu¨nchen
Labofuge GL Heraeus Sepatech
Rotors:
JA10, JA 20 Beckmann, Mu¨nchen
Ti 45, Ti 60, Ti 70 Beckmann, Mu¨nchen
TLA 45, Beckmann, Mu¨nchen
TLA-100.3 Beckmann, Mu¨nchen
Electrophoresis chambers for agarose gels Workshop of the Institute
Electrophoresis chambers for polyacrilamide gels Workshop of the Institute
Liquid scintillation counter 1900TR Packard, Frankfurt/Main
Gel dryer Bio-Rad, Hilden
Magnetic mixer IKA, Works, INC.
MALDI-TOF Mass Spectrometer, REFLEX III Bruker Daltonics, Bremen
Microwave oven Siemens, Mu¨nchen
pH-Meter Beckmann, Mu¨nchen
Photometer, UV 160 A Shimadzu, Kioto/Japan
UV-hand lamp (365/254nm), Type 5415 and 5402 Eppendorf, Hamburg
Vacuum concentrator model 100H Bachhofer, Reutlingen
Vortex-Genie Scientific Industries, USA.
DNA-Sequencer Type 310 ABI, PE Biosystems
Electroporator 1000 (used for bacteria) Stratagene, USA
Confocal Laser Scanning Microscope Leica, Bensheim
Leica TCS SP2 AOBS
(Ar: 488, 514 nm; He/Ne: 543 nm; 63x Oil Objective)
Incubators Innova 4230 and 4330 New Brunswick Scintific
Phosphoimager Fujix BAS1000 Fuji, Japan
Ultra turrax T8 IKA Labortechnik, Staufenv
Supersignal Chemiluminiscent Substrate Pierce, Illinois
Thermocycler GeneAmp PCR system 9600 Perkin-Elmer Cetus
2.1.2 Chemicals, plasticware and membranes
Chemicals Boehringer/Roche, Mannheim,
Merck, Darmstadt,
Roth, Karlsruhe,
Serva, Heidelberg,
Sigma, Deisenhofen
Cell culture plasticware Greiner, Frickenhausen
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Nalge Nunc International, Denmark
Nitrocellulose membrane Schleich and Schu¨ll, Dassel
PVDF membrane, 0.2µM Schleich and Schu¨ll, Dassel
Hybond-N Nylon membrane Amersham Biosciences, UK
Whatman GB002 paper Schleich and Schu¨ll, Dassel
Whatman GB003 paper extra thick Schleich and Schu¨ll, Dassel
2.1.3 Kits, spin columns and reagents
DNA, RNA:
HiSpeed Plasmid Midi kit Qiagen
Omniscript Reverse Transcription kit Qiagen
PCR purification kit Qiagen
QIAprep Spin Miniprep kit Qiagen
QIAquick Gel Extraction kit Qiagen
Rapid-hyb hybridisation buffer Amersham Pharmacia Biotech
rediprimeTMII labeling system Amersham Pharmacia Biotech
RNAlater RNA Stabilisation Reagent Qiagen
RNase inhibitor RNase Out Invitrogen
RNeasy Mini and Midi Kit Qiagen
TA Cloning Kit Invitrogen
Effectene Transfection kit Qiagen
Fugene Transfection reagent Roche
Lipofectamine 2000 Invitrogen
Protein:
Bio-Rad Protein Assay Bio-Rad
DAKO fluorescent mounting medium DakoCytomation, USA
ECL Plus Amersham Biosciences
ConcanavalinA-Sepharose 4B Amersham Biosciences
Ni-agarose Qiagen
Protease Inhibitor Cocktail Sigma
PD-10 Sephadex G-25 M column Amersham Pharmacia Biotech
Sep-Pak C18 Cartridge Waters, USA
Stimune Adjuvant Cedi Diagnostics B. V., Netherlands
Supersignal Chemiluminescence Kit Pierce, USA
Roti-blue Colloidal Coomassie Brilliant Blue Roth
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Titermax Gold Adjuvant Sigma
Vivaspin Vivascience, Goettingen
Bovine Serum Albimin (BSA) Serva
Iodoacetamide, Iodoacetic acid Sigma
PANSORBIN cells Calbiochem
Protein A sepharose Sigma
Protein G agarose Sigma
Prestained Marker Biorad
2.1.4 Vectors and DNA standards
pBI BD CLONTECH
pSB 4.7 pA Transkaryotic Therapies Inc, Cambridge, MA
pSV-pac gift from Prof. Stefan Ho¨ning
pGK Hygro Invitrogen life technologies
pUB/Bsd Invitrogen life technologies
1-kb DNA ladder Gibco BRL
2.1.5 Antibiotics and drugs
Ampicillin Serva
Blasticidin-S Hydrochloride Invitrogen life technologies
Hygromycin Calbiochem
Neomycin (Gentamycin sulfate or G418) Gibco
Penicillin/Streptomycin Gibco
(100 x =10,000 U/ml)
2.1.6 Radioactive substances
[35S]-Methionine, 10 mCi/ml Amersham Pharmacia Biotech
2.1.7 Enzymes, substrates and nucleotides
Restriction endonucleases New England Biolabs
Klenow DNA polymerase New England Biolabs
DNA ligase New England Biolabs
Taq DNA polymerase Amersham Pharmacia Biotech
Alkaline phosphatase Boehringer
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Ultrapure dNTP Set Amersham Pharmacia Biotech
Adenosine 5’-triphosphate (ATP) Sigma
Endoglycosidase H, PNGase Roche Diagnostics
2.1.8 Primary antibodies
antigen type western blot reference
RGS-His6 tag mouse mAb 1:2000 Qiagen
HA tag mouse mAb 1:2000 Covance Inc., Princeton
pFGE rabbit pAb 1:2500 this study
pFGE mouse mAb 1:2500 this study
FGE rabbit pAb 1:2500 this study
FGE mouse mAb 1:2500 this study
Galactose-6-sulfatase mouse mAb 1:1000 Transkaryotic
Therapies, Inc, USA
Steroid sulfatase rabbit pAb 1:5000
Arylsulfatase A rabbit pAb 1:10000
2.1.9 Secondary antibodies
Goat anti-rabbit Horseradish peroxidase conjugate
Goat anti-mouse Horseradish peroxidase conjugate
Goat anti-rabbit Cy3 conjugate
Goat anti-mouse Cy2 conjugate
Goat anti-mouse Cy3 conjugate
Goat anti-mouse Cy2 conjugate
All secondary antibodies were purchased from Dianova, Hamburg.
2.1.10 Stock solutions and buffers
1 M Sodiumphosphate buffer
1 M solution of sodium di-hydrogen phosphate was slowly added to 1 M di-sodium
hydrogenphosphate solution with constant mixing on a magnetic stirrer till the pH
came down to 7.4.
10 x PBS
100 mM sodium phosphate pH 7.4
9 % sodium chloride
Dissolved in 800 ml water and pH was adjusted to 7.4 with HCl, volume was made
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up to 1000 ml and autoclaved. Stored at room temperature.
1 x TBS
10 mM Tris/ HCl pH 7.4
150 mM Sodium chloride
1 x TAE 0.04 M Tris-acetate
1mM EDTA (pH 8.0)
50x TAE
242 g Tris base
57.1 g glacial acetic acid
100 ml of 0.5 M EDTA (pH 8.0)
Dissolved in water and the final volume was made upto one litre.
TE Buffer
10 mM Tris/ HCl pH 7.5
1 mM EDTA
2.2 Molecular Biology Methods
2.2.1 Cultivation of E.coli
Luria Bertani (LB) medium
10 g Bacto-Tryptone
5 g Bacto-yeast extract
5 g NaCl
Dissolved in 900 ml distilled water, pH adjusted to 7.0 with 10 N NaOH, made up
the volume to one liter, sterilized by autoclaving and stored at room temperature.
LB-Ampicillin Agar Plates
1.5% of Agar was added to the LB medium and autoclaved. After autoclaving,
the medium was let to cool down to 55◦C and ampicillin was added to a final
concentration of 100µg/ml. This medium was poured into 10 cm petriplates in
the hood and left undisturbed for about 30 min to solidify. LB-Agar plates were
stored in the cold room.
Preparation of competent E. coli cells
Buffers
TFB I 30 mM Calcium acetate, pH 5.8
100 mM Rubidium chloride
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10 mM Calcium chloride
50 mM Manganese chloride
15% Glycerol (w/v)
TFB II 10 mM MOPS, pH 6.5
75 mM Calcium chloride
10 mM Rubidium chloride
15% (w/v) Glycerol
2-3 ml bacterial pre-culture was grown in LB medium at 37◦C overnight. 1
ml of the pre-culture was then inoculated into 99 ml of LB medium and grown
at 37◦C to an O.D 600 of 0.4-0.6. Cells were pelleted at 3,000 rpm for 5 min at
4◦C, resuspended cell pellet in 1/3 of the original volume ice-cold buffer TFB I and
incubated on ice for 5 min. Cells were centrifuged at 3000 rpm for 5 min at 4◦C,
the pellet was resuspended in about 1/25 of the original volume ice-cold buffer TFB
II and incubated on ice for 30 min. Aliquots of 50µl were frozen in liquid nitrogen
and stored at -80◦C.
2.2.2 Transformation of E.coli competent cells
50-100 ng of DNA was added to each 50µl aliquot of competent cells and incubated
on ice for 30 min. Cells were subjected to heat shock by incubating at 42◦C for 2
min and incubated on ice for 1-2 min. 0.9 ml of LB medium was added to the cells
followed by incubation at 37◦C in the shaker for 1 hour. Cells were plated on LB-
agar plates containing appropriate antibiotic. For blue-white selection, cells were
plated on plates containing IPTG (Isopropyl-β-Dthiogalactopyrahoside; 40 µl of 100
mM solution in water) and X-Gal (40µl of 4% solution in dimethylformamide).
2.2.3 Preparation of electrocompetent DH5α cells
10% (v/v) Glycerol : 1 ml (1.26 g) of glycerol in 10 ml sterile water
A single E. coli colony was inoculated into 5 ml of LB media and allowed to grow
overnight at 37◦C in a shaker incubator. 2.5 ml of this pre-culture was inoculated
into 500 ml LB media and allowed to grow to an OD 600 of 0.5-0.7 at 37◦C. Cells
were pre-chilled on ice for 15 min and then pelleted at 5000 rpm for 15 min at 4◦C.
Pellet was resuspended in 500 ml of ice cold water and centrifuged as described
above. This washing was repeated one more time. To the pellet an equal volume of
10% glycerol was added and resuspended, aliquots of 100µl were stored at -80oC.
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2.2.4 Transformation of the electrocompetent cells
SOC medium
0.5% Yeast extract
2% Bacto-tryptone
10 mM Sodium chloride
2,5 mM Potassium chloride
10 mM Magnesium sulfate
10 mM Magnesium chloride
20 mM Glucose
For each electroporation 40µl of the electrocompetent cells were used. 0.5ng of
DNA was added to the cells and the contents were transferred into a pre-chilled
electroporation cuvette. The cuvette was placed in the electroporater and pulse was
applied. SOC medium was added to the cells and they were allowed to recover in
sterile tubes for 30 min at 37◦C in a shaker incubator. Cells were plated on LB plates
containing appropriate antibiotic.
2.2.5 Glycerol stocks of bacterial strains
Bacterial cultures were grown overnight at 37◦C in a shaker-incubator. 0.3 ml of
sterile 100% glycerol was taken in freezing vials to which 700µl of the overnight
culture was added. The contents were gently mixed, shock frozen on dry ice and
stored at -80◦CC.
2.2.6 Mini preparation of plasmid DNA
Plasmid DNA was isolated from E.coli cultures using the Qiagen. Isolation was done
according to the instructions of the manufacturer.
Buffer P1 50 mM Tris/ HCl pH 8,0
10 mM EDTA
100 µg/ml RNase A
Buffer P2 0.2 M NaOH
1% SDS
Buffer P3 3 M Potassium acetate pH 5.5
Single E. coli colony was inoculated into 3 ml of LB medium containing
100µg/ml of antibiotic and grown overnight at 37oC in a shaker incubator. Cells
were pelleted in a table-top centrifuge at 3,000 rpm for 5 min. Cell pellet was
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resuspended in 250 µl of buffer P1 and 250µl of buffer P2 was added, mixed gently
by inverting the tube 4-6 times. To this, 350 µl of buffer P3 was added and gently
mixed and centrifuged for 10 min at 13,000 rpm in a table-top eppendorf centrifuge.
The supernatant was applied onto a QIAprep spin column and centrifuged for 1 min
at 13,000 rpm. Flow through was discarded, the column was washed with 0.75 ml
of buffer PE and centrifuged again for 1 min. Flow through was discarded and the
column was centrifuged for an additional 1 min to remove any residual wash buffer.
The column was placed in a clean eppendorf tube and 50 µl of double distilled water
was added directly to the centre of the column. The column was let to stand for 1
min and DNA was eluted by centrifuging at 13,000 rpm for 1 min.
2.2.7 Determining the concentration of DNA
DNA concentration was determined using a spectrophotometer. DNA was diluted
in water and the absorbance was measured at 260 nm. Absorbance or optical
density (OD) of 1 at 260 nm corresponds to ∼50µg/ml of double stranded DNA
or ∼40µg/ml of single stranded DNA and RNA or ∼20µg/ml of oligonucleotides.
The ratio between the readings at 260 nm and 280 nm (OD260/ OD280) provides
an estimate of the purity of the nucleic acid. Pure preparations of DNA and RNA
have OD-260/OD-280 values of 1.8 and 2.0, respectively. Any contamination with
proteins or phenol would yield values less than mentioned above.
2.2.8 Restriction endonuclease digestion of DNA
The activity of restriction enzymes is measured in terms of ‘Units’ (U).
One unit of restriction enzyme is the amount of enzyme required to completely
digest 1µg substrate DNA in 1hr.
Plasmid DNA 0.5 - 1µg
10 x buffer 2µl
Restriction enzyme 1-2 U
BSA 1µg/µl (added where essential)
Water was added to a final volume of 20µl. Reaction mix was incubated at 37◦C*
for 2 hours.
*Incubation temperatures were set as recommended by the manufacturer (New
England Bio Labs Beverly U.S.A.) which varies from enzyme to enzyme. Reaction
mix was analyzed on agarose gel (0.8 to 2% depending on the size of the DNA of
interest) The buffers and enzymes used were all from New England Biolabs. The
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composition of the buffers is as follows:
NEB 1: 10 mM Bis Tris Propane-HCl (pH 7.0), 10 mM MgCl2, 1 mM DTT
NEB 2: 10 mM Tris-HCl (pH 7.9), 10 mM MgCl2, 50 mM NaCl, 1 mM DTT
NEB 3: 50 mM Tris-HCl (pH 7.9), 10 mM MgCl2, 100 mM NaCl, 1 mM DTT
NEB 4: 20 mM Tris-acetate (pH 7.9), 10 mM Magnesium acetate, 1 mM DTT, 50
mM Potassium acetate
2.2.9 Agarose gel electrophoresis of DNA
The size and purity of DNA is analyzed by agarose gel electrophoresis. Concentra-
tion of agarose used for analysis is inversely proportional to the size of the DNA of
interest, that is, the larger the DNA the lower the concentration of agarose.
Agarose concentration (%) DNA size (kb)
0.7 20 - 1
0.9 7 - 0.5
1.2 6 - 0.4
1.5 4 - 0.2
2.0 3 - 0.1
Gel loading buffer (10x) 0.25% (w/v) Bromophenol blue
40% Saccharose in 1x TAE
Agarose was weighed and dissolved in 1 x TAE by boiling in microwave oven.
The agarose solution was cooled to 60◦C and ethidium bromide was added to a
final concentration of 0.5µg/ml. This was poured into the agarose gel cassette
and allowed to polymerize completely. The sample DNA was mixed with gel
loading buffer and loaded onto the gel. The gel electrophoresis was carried out
at 100 V. Ethidium bromide is a fluorescent dye which contains a planar group that
intercalates between the stacked bases of the DNA. The fixed position of this group
and its close proximity to the bases cause the dye to bound to DNA. It results in an
increased fluorescent yield compared to that of the dye in free solution. Ultraviolet
radiation at 254 nm is absorbed by the DNA and transmitted to the dye; radiation at
302 nm and 366 nm is absorbed by the bound dye itself. In both cases, the energy is
re-emitted at 590 nm in the red orange region of the visible spectrum. Hence DNA
can be visualized under a UV transilluminator. The gel was photographed using a
gel documentation system.
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2.2.10 Cloning of human pFGE encoding cDNA (SUMF2)
Total RNA, prepared from human fibroblasts using the RNeasy Mini kit
(Qiagen), was reverse-transcribed using the Omniscript reverse transcriptase
kit (Qiagen), and either an oligo(dT) primer or the SUMF2-specific primer
1072nc(5’GGAAGGGGAAGTTCTTTCC-3’). The first strand cDNA was amplified
by PCR using the forward primer 1c (5’-ATGCGCAGCGGGGCCGTGG-3’) and, as
reverse primer, either 1072nc or 1049nc (5’-GCTGAAGCTCTCGAGCTTGG-3’).
The PCR products were cloned directly into the pCR4-TOPO vector (Invitrogen).
By sequencing multiples of the cloned PCR products, which had been obtained
from various individuals and from independent reverse transcriptase and PCR
reactions, the cDNA sequence coding for pFGE (906 bp from start to stop codon)
was established. The sequence corresponds to entry to GenBank entry NM-015411
but deviates in one position (87C>T). This change is a silent mutation in the third
position of the serine 29 codon and may reflect a polymorphism.
2.2.11 Construction of expression plasmids
The pFGE encoding cDNA was equipped with a 5’ BamHI site and a 3’ RGS-His6 tag
sequence followed by a stop codon and a XbaI site, by add-on PCR using Pfu Ultra
polymerase (Stratagene) and primers 5’-CGGGATCCACCATGGCCCGGCATGGGTTAC-
3’ (BamHI) and 5’-GCTCTAGATTAGTGATGGTGATGGTGATGCGATCCTCTCAGCTCC
CCTGGCGGC-3’ (RGS-His6-XbaI). The resulting PCR product was cloned as
a BamHI/XbaI fragment downstream of the cytomegalovirus promotor of the
expression vector pSB4.7pA, which was provided by Transkaryotic Therapies Inc.
(Cambridge, MA).
For coexpression of FGE or pFGE with steroid sulfatase, the pBI vector
(BD Biosciences) was used, which allows expression of two cDNAs from a
bidirectional tet-responsive promotor. The FGE- and pFGE-encoding cDNAs
were equipped with a 5’ EcoRV site and a 3’ HA tag sequence followed by
a stop codon and a NotI site, by add-on PCR using Pfu Ultra polymerase
(Stratagene) and the following primers: 5’-GGATATCGGGACAACATGGCTGCG-
3’ (EcoRV-FGE); 5’-GGATATCACCATGGCCCGGCATGGGTTAC-3’ (EcoRV-pFGE); 5’-
ATAGTTTAGCGGCCGCTTATGCGTAGTCAGGCACATCATACGGATAGTCCATGGTGGGC
AGGC-3’ (FGE-HA-NotI); 5’-ATAGTTTAGCGGCCGCTTATGCGTAGTCAGGCACATCATA
CGGATACAGCTCCCCTGGCGGC-3’ (pFGE-HA-NotI).
The EcoRV/NotI-digested PCR products were inserted into the multiple
cloning site II of the pBI vector that had been opened by PstI, blunted with
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T4-polymerase/dNTPs, and cut with NotI. It should be noted that after ligation,
the initial EcoRV and PstI sites were destroyed. Into the multiple cloning site I of
the obtained constructs and of the empty pBI vector, the steroid sulfatase cDNA
was cloned as an NheI/EcoRV fragment. This fragment was generated from a PCR
product that was obtained using pBEH-STS as template, Pfu Ultra polymerase, and
add-on primers 5’-CTAGCTAGCCACCATGCCTTTAAGGAAGATGAAG-3’ (NheI) and
5’-GGATATCAGCGGCTCAGTCTCTTATCC-3’ (EcoRV).
2.2.12 Northern blot analysis
A human multi tissue Northern blot (BD Biosciences) was hybridized with 32P-
labelled cDNA probes covering the entire coding regions of FGE or pFGE, respec-
tively, and a β-actin cDNA probe as a control for RNA loading. Basically the same
result, as shown in Fig.3.2.A, was obtained when using probes hybridizing in the
3’ UTR regions of SUMF1 or SUMF2 mRNA, where the two sequences show no
similarity (not shown). It was verified before each hybridization round that no
radioactivity had remained from the previous hybridization. For technical details
refer[53].
2.3 Cell culture and transfections
2.3.1 Basics
Normal growth medium: DMEM, 10% fetal calf serum, Pen-Strep
Trypsin-EDTA solution: 0.5 g/l Trypsin, 0.2 g/l EDTA
phosphate-buffered saline (PBS): 150 mM NaCl, 120 mM KCl,
10 mM Na2HPO2/KH2PO2 pH 7.4
Freezing medium: 10% DMSO in normal growth medium
HT1080 cells and Human skin fibroblasts cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1%
penicillin/streptomycin (Invitrogen) under 5% CO2 at 37◦C.
Passaging by trypsinisation
Cell line was passaged every 2-7 days depending on the growth rate. After two
washes with PBS, 0.5 ml trypsin solution per 25 cm2 was added to the cell layer.
The cells were incubated at 37 ◦C for 5 min, then singled by tapping to the dish and
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resuspended in medium. To concentrate, wash or harvest cells, centrifugation was
always done at 500xg for 5 min.
Freezing cells for stock maintenance
Usually, cells from a confluent 35 cm2 flask were frozen as 2-4 vials. Cells were
pelleted after trypsinisation, resuspended in 1 ml freezing medium per vial, imme-
diately placed on ice and stored at -80 ◦C overnight. The vials were transferred to
the liquid nitrogen container the following day.
Thawing cells
The frozen vial was taken out of liquid nitrogen, the cap was carefully loosened
to release pressure and the vial was thawed in 70% ethanol at 37 ◦C, until the
suspension had almost completely melted. Under the hood, the cells were then
transferred to a tube containing 5 ml chilled cell culture medium. The cells were
pelleted, resuspended in prewarmed culture medium and transferred to a culture
flask. Medium was replaced on the next day.
2.3.2 Transfections
Transient transfection
Transient transfection was performed with Lipofectamine 2000 following the pro-
tocol recommended by Invitrogen. Typically, 4 µg of plasmid DNA were used per
6-cm dish. For coexpression experiments, the cells were transfected with a mix
of 2 µg of pBI vector containing pFGE-(or FGE-) and steroid sulfatase-encoding
cDNAs plus 2 µg of rtTA plasmid (reverse tetracycline controlled transactivator, BD
Biosciences). For triple expression experiments, the cells were transfected with a
mixture of three plasmids: 1 µg of pBI vector containing only pFGE cDNA, 1 µg
of pBI vector containing FGE, and steroid sulfatase cDNAs and 2 µg of rtTA vector.
After 6 hr, the medium was replaced with medium containing 1 µg/ml doxycyline
(BD Biosciences), and 30 hr later, the cells were harvested for further analysis.
Stable transfection
HT1080 cells in 6cm dishes were transfected with pSB-pFGE-His or FGE-His using
Lipofectamine 2000 as mentioned above. After 36h, cells were transferred to two
100-mm dishes at a 1:20 dilution and cultured for 2 weeks in normal growth
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medium containing genticin (G418 sulfate; Invitrogen) with an increasing concen-
tration from 200 to 800µg/ml. Drug resistant clones were picked and expanded in
growth medium containing genticin (800µg/ml). Clones were screened by western
blot analysis for expression of the appropriate protein. HT1080 cells stably express-
ing galactose-6-sulfatase (kindly gifted by Transkaryotic Therapies Inc, Cambridge,
MA) were transfected with pSB-pFGE-His or FGE-His plus puromycin resistance
vector (10:1 ratio) using Lipofectamine 2000. After 36hr, cells were passaged to
two 100 mm dishes and cultured for two to three weeks in normal growth medium
containing puromycin (Invitrogen) with an increasing concentration from 0.2 to
0.8µg/ml. The drug resistant clones were expanded and screened by western
blotting.
2.4 Biochemical Methods
2.4.1 Analysis of Protein
Protein estimation by BIORAD reagent
Bovine Serum Albumin (BSA) stock solution 1 mg/ml
Concentration range : 2 -16µg/µl
A standard curve was made using BSA in the range of 2 -16µg. 10µl of the sample
was used for the protein estimation. The sample volume was made up to 800µl
with water. 200µl of the BIORAD reagent was added to each samples, votexed and
incubated for 3 - 5 min at room temperature, 200µl from each tube was pipetted
into ELISA strips and optical density was measured at 595 nm in the ELISA reader.
Solubilisation of proteins
2 x Laemmli buffer
125 mM Tris-Cl, pH 6.8
4% SDS
0.004%Bromophenol blue
20% (w/v) Glycerol
10% β-mercaptoethanol
Protein samples after speed vac were resuspended in 1x Laemmli buffer. The
resuspended proteins were boiled at 95◦C for 5 min, cooled on ice for 1 min,
centrifuged at 13,000 rpm for 2 min and resolved by SDS-PAGE.
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2.4.2 SDS-Polyacrylamide Gel Electrophoresis (Laemmli et al.,
1970)
The elecrophoretic separation of the proteins was performed through high-tris dis-
continual SDS polyacrylamide gel electrophoresis. A system with vertical oriented
glass plates (16 x 16 cm; 1 mm spacer) was used. The gels were prepared as follows:
first the resolving gel (12.5-17.5% acrylamide) was put between glass plates and
covered with a layer of butanol. After polymerisation of the gel was completed,
butanol was removed and the space between glass plates was dried with Watmann
paper. Then the concentrating gel was put on top of the polymerised resolving gel
and the sample combs were introduced immediately. After approximately 15 min
polymerisation was completed and the sample combs were removed. The glass
plates with the gel between them were fixed inside the electrophoresis chamber
and covered with electrophoresis buffer. Protein samples were mixed with Laemmli
loading buffer 1:1, denatured by 95 ◦C and centrifuged with 14000 rpm. The
supernatant was introduced into the stacking gel pockets. Electrophoresis was
performed for 2-3 hours with the constant current of 35 mA.
Electrophoresis buffer:
SDS (w/v) – 10g/10 litre
Glycine (w/v)– 144,27g/10 litre
Tris (w/v) – 60,53g/10 litre
20% Ammoniumperoxiddisulfate (APS) in ddH2O
Stacking gel(1X)
Ingredients 5%
30% Acrylamide solution: (ml) 0.4
1% bisacrylamide solution (ml) 0.275
ddH2O (ml) 1.175
0,5 M Tris-HCl, pH 6.8 (ml) 0.625
(10%) SDS (µl) 25
TEMED (µl) 2.5
(20%) APS (µl) 10
Separating gel (1X)
Ingredients 15%
30% Acrylamide solution: (ml) 8.75
34 Chapter2. Materials and Methods
1% bisacrylamide solution (ml) 2.74
ddH2O (ml) 1.4
1.5 M Tris-HCl, pH 8.8 (ml) 4.3
(10%) SDS (µl) 175
TEMED (µl) 14.58
(20%) APS (µl) 58.33
2.4.3 Detection of proteins in polyacrylamide gels
Staining with Roti-Blue Colloidal Coomassie
Colloidal Coomassie staining is one of the most sensitive staining protocols. Due
to the colloidal properties of the dye, it binds with high specificity to proteins and
only minimal to the gel matrix. This allows visualisation of proteins separated by
SDS-PAGE with sensitivity as high as 30ng of protein. Roti-Blue collodial Coomassie
was purchased from Roth and staining was performed according to the protocol as
follows. Immediately after completion of electrophoresis, gels were incubated in
the fixing solution for 60 min, shaking. The staining solution was applied on to
the gels for 60 min. In special cases the gels were stained for several days, which
improved the sensitivity of the staining. After staining, gels were incubated in the
washing solution for 5-10 min and then kept in the stabilising solution or prepared
for drying in the drying solution.
Fixing solution: 20% (v/v) methanol
8.5% (v/v) o-phosphoric acid
Staining solution: 20% (v/v) methanol
20% (v/v) 5x concentrate Roti-Blue colloidal Coomassie
Washing solution: 25% (v/v) methanol
Stabilising solution: 20% (w/v) ammonium sulphate
Drying solution: 10% (v/v) glycerol
20% (v/v) ethanol
2.4.4 Western blot (semi-dry)
Cathode buffer 40 mM -aminocaproic acid, 20 mM Tris-Cl,
20% (v/v) methanol, pH 9.0 (pH was adjusted
with free Tris base before addition of methanol)
Anode buffer 75 mM Tris-Cl, 20% (v/v) methanol, pH 7.4
Phosphate-buffered saline (PBS) 140 mM NaCl, 2.7 mM KCl, 10mM-
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Na2HPO4, 1.8 mM KH2PO2, pH 7.3
PBST 0.1% (v/v) Tween-20 in PBS
Blocking buffer 5% milk powder in PBST
Glycine stripping solution 0.2 M glycine pH 2.8, 0.5 M NaCl
SDS stripping solution 16 mM Tris-Cl pH 6.8, 2% SDS,
0.1 M -mercaptoethanol
Six pieces of 3 mm Whatman paper and one piece of nitrocellulose membrane were
cut to the size of the SDS gel. Gel and membrane were equilibrated for 5-15 min
in cathode buffer. The blot was assembled without air bubbles according to the
following scheme:
cathode (-)
3x paper in cathode buffer
gel
membrane
3x paper in anode buffer
anode (+)
For transfer, the current was set to 1 mA/cm2 gel size for 45-60 min. The membrane
was then briefly washed with PBST and incubated in blocking buffer for one hour at
room temperature. Decoration with the primary antibody diluted in blocking buffer
occurred overnight at 4 ◦C. After three 30-45 min washes with PBST, the membrane
was incubated with horse radish peroxidase (HRP)-coupled secondary antibody,
diluted 1:10 000 in blocking buffer, for one hour at room temperature. The blot was
washed three times 30-45 min with PBST and incubated with chemiluminescence
substrate solution. Intelligent Dark Box II Camera was used for signal detection.
Stripping of nitrocellulose membranes
Removal of antibodies from a blot was done under mild conditions, if it should serve
to reduce the background for incubation with another primary antibody, either from
a different species or for a protein of clearly distinct size than in the first decoration.
After washing the membrane in PBST, it was incubated 5-20 min in glycine stripping
solution. The solution was neutralised with 1 M Tris-Cl pH 8.5, followed by several
washes in PBST. If it was crucial to remove antibodies completely, the blot was
incubated in SDS stripping solution for 30 min, tightly closed, on a wheel at 50
◦C, followed by several washes in PBST. Decoration of the membrane was done as
described above, starting from the blocking step again.
36 Chapter2. Materials and Methods
2.4.5 Detection of radioactively labelled polypeptides
For detection of radioactively labelled polypeptides polyacrylamide gels were fixed
in destaining solution for 15 min and then washed with water for 30 min. Then
the gels were dried between cellophane layers in the gel-dryer for 2 hours. For
visualisation of the incorporated radioactive label the gels were exposed on to the
Imaging plate (Fuji) overnight or longer period at RT. The image on the plate was
analysed by the program Image reader (Fuji-Film, Vers. 1.4 E) with the help of the
BAS 1000 phosphoimager (Ray-test).
2.4.6 Staining with silver (Schevchenko et al., 1996)
Staining of proteins separated on SDS-gel with silver allows quick and effective
visualization of even small amounts of protein. After completion of electrophoresis
gels were incubated with shaking in fixing solution for 1 hour. After that gels were
washed 2 times for 20 min in 30% ethanol and equilibrated for 20 min in water.
Equilibrated gels were washed for 1 min in 0.03% Na2S2O3, washed with water
and incubated in staining solution for 20 min at 4◦C. Then the gels were washed in
water twice for 30 seconds and developed in the developing solution until desired
intensity of the bands was obtained. Developing was stopped by transferring the
gels into a new chamber with 5% acetic acid. Gels were kept in 1% acetic acid or
washed with water to prepare them for drying.
Fixing solution: 10% (v/v) acetic acid
40% (v/v) ethanol
Staining solution: 0.2% (w/v) silver nitrate
0,008% (v/v) formic aldehyde
Developing solution: 3% (w/v) sodium bicarbonate
0,018% (v/v) formic aldehyde
2.4.7 In vitro assay for FGE
For monitoring the activity of FGE, the N-acetylated and C-amidated 23-mer peptide
P23 (MTDFYVPVSLCTPSRAALLTGRS) was used as substrate. The conversion of the
cysteine residue in position 11 to FGly was monitored by MALDI-TOF mass spec-
trometry. A 6 µM stock solution of P23 in 30% acetonitrile and 0.1% trifluoroacetic
acid (TFA) was prepared. Under standard conditions, 6 pmol P23 were incubated at
37 oC with up to 10 µl enzyme in a final volume of 30 µl 50 mM Tris/HCl (pH 9.0),
containing 67 mM NaCl, 15 M CaCl2, 2 mM DTT, and 0.33 mg/ml bovine serum
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albumin. To stop the enzyme reaction, 2 µl 10% TFA was added. P23 then was
bound to ZipTip C18 (Millipore), washed with 0.1% TFA, and eluted in 3 µl 50%
acetonitrile, 0.1% TFA. 0.5 µl of the eluate was mixed with 0.5 µl of matrix solution
(5 mg/ml -cyano-4-hydroxy-cinnamic acid (Bruker Daltonics) in 50% acetonitrile,
0.1% TFA) on a stainless steel target. MALDI-TOF mass spectrometry was done with
a Reflex III (Bruker Daltonics) using reflectron mode and laser energy just above the
desorption/ionization threshold. All spectra were averages of 200-300 shots from
several spots on the target. The mass axis was calibrated using peptides of molecular
masses ranging from 1000-3000 Da as external standards. Monoisotopic MH of P23
is 2526.28 and of the FGly containing product 2508.29. Activity (pmol product/hr)
was calculated on the basis of the peak height of the product divided by the sum of
the peak heights of P23 and the product.
2.4.8 Determination of FGE activity in cells
The trypsinized cells were washed with phosphate-buffered saline (PBS) and resus-
pended in 10 mM Tris (pH 8.0), containing 2.5 mM DTT, the proteinase inhibitor
cocktail (Sigma). The cells were lysed by ultrasonication and cleared by centrifuga-
tion at 125,000 Xg for 30min. The supernatant was subjected to chromatography
on a MonoQ PC 1.6/5 column using a 1 ml gradient of 0 to 375 mM NaCl in the
Tris buffer described above and a flow rate of 0.1 ml/min. Fractions eluting at
50-200mM NaCl were pooled, lyophilized, and reconstituted in one-tenth of the
original pool volume prior to determination of FGE activity with peptide P23.
2.4.9 Sulfatase assays
Activity of ASA, STS, and galactose-6-sulfatase were determined as described (Rom-
merskirch and von Figura, 1992; Glo¨ssl and Kresse, 1978).
2.4.10 Purification of recombinant pFGE-His
HT1080 cells stably overexpressing pFGE-His were grown to near confluence in
normal growth medium. After 48h, the medium was collected and fresh medium
was added. Medium can be collected up to 8 times for purification of pFGE-
His. The medium was spun down at 1100 X g (JA10 rotor) for 30 minutes and
the supernatant was precipitated by 50% ammonium sulfate. The precipitated
medium was centrifuged at 11300 Xg (JA10) for 30 minutes and the pellet was
reconstituted in lysis buffer (50mM NaH2PO4, 300mM NaCl and 10mM Imidazole).
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The suspension was dialyzed against lysis buffer for 16h. The dialysed material was
cleared (142414 X g, Ti45 rotor, 30min, 4◦C) and subjected to Ni2+-NTA affinity
chromatography under the conditions recommended by the manufacturer (Qiagen).
Peak fractions, analysed by western blotting were pooled and dialysed against buffer
A (10mM Tris-Hcl pH8.0, 100mM NaCl, 2.5mM DTT) for overnight. The dialysed
pFGE-His was applied to a MonoQHR10/10 anion exchange column (Amersham
Biosciences) equilibrated with Buffer A. The unbound pFGE-His was recovered in
the flow through and other contaminants were eluted with a linear gradient to 400
mM NaCl in buffer A. The flow through fractions were pooled and concentrated by
Ultrathimble (Schleicher and Schuell). 50 µg of pFGE-His applied to a Superdex
200 gel-filteration column (Amersham Biosciences) that had been equilibrated in
PBS and eluted isocratically with PBS. Peak fractions were run on a 15% SDS
polyacrylamide gel and followed by staining with Coomassie Brilliant Blue.
2.4.11 Immunisation of rabbits and serum preparation
Rabbits were housed by the animal facility of the medical faculty.
Preparation of antigen emulsions for immunisation:
300 µg and 200 µg of purified pFGE-His from secretion was emulsified for the first
injection and subsequent booster injections, respectively. Stimune or Titermax Gold
served as adjuvant. Pre-immune serum was collected before immunization to use
as a negative control in western blots and immunoprecipitations. Booster injections
were given once in two weeks and bleeds were collected two weeks after booster
injections and analyzed by Western blot. The rabbit was sacrificed two weeks after
the fourth booster injection.
Preparation of serum from blood samples:
Blood samples were incubated for 4 h at room temperature or overnight at 4◦C
to allow for clot formation and centrifuged for 15 min at 13,000 Xg and 4◦C. The
supernatant was carefully transferred into new tubes. Small aliquots were either
frozen at -20 ◦C or at -80 ◦C for long term storage.
2.4.12 Gel filtration on a Superdex-200
HT1080 cells stably expressing galactose-6-sulfatase and FGE-His or pFGE-His were
grown to near confluence in 100-mm dishes. Cells were harvested by scrapping and
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lysed in 2ml of PBS by ultrasonication. The cell lysate was cleared by centrifugation
at 125,000 Xg for 30 min at 4 ◦C. 50 µl of supernatent was subjected to Superdex-
200 PC 3.2 (2.4 ml) which had been equilibrated with PBS. The column was
eluted with the same buffer at flow rate of 0.04 ml/min. Fractions, each 0.08
ml were collected and run on 15% SDS-polyacrylamide gel. After transferring to
nitrocellulose membrane, probed with a mixture of monoclonal antibodies against
galactose-6-sulfatase and His-tag.
For coelution of purified pFGE-His and FGE-His, both were mixted in a 2:1 molar
ratio and incubated at room temperature for 30 min. The reaction was carried out
in PBS at pH 7.4. Then the mixture was passed through Superdex-200 as described
above. Protein fractions were analysed by Western blot using His-tag monoclonal
antibody.
2.4.13 In Vivo and in vitro protein-protein cross-linking
In vivo– HT1080 cells trasiently expressing pFGE and FGE were grown on 60-mm
plates. Cells were washed two times with phosphate-buffered saline (PBS) at room
temperature and mixed with 5 ml of PBS, and dithiobis (succinimidyl propionate)
(DSP) dissolved in Me2SO was added to a final concentration of 2 mM. The plates
were incubated on ice for 30 min, and the reaction was quenched by adding 5
ml of TE buffer (50 mM Tris-HCl, pH 7.6). Cells were further washed twice with
PBS and harvested by scrapping. The cell pellet was resuspended in PBS and lysed
by ultrasonication. For western blot analysis, equal volume of cell extracts were
applied for SDS-PAGE under reducing and non-reducing conditions (with or without
50 mM DTT), transfered to nitrocellulose membrane, and probed with FGE or
pFGE antiserum and horse radish peroxidase-conjugated goat anti-rabbit antibody,
as primary and secondary antibody, respectively.
In vitro– Purified pFGE-His and FGE-His were mixed in 2:1 molar ratio and incu-
bated at 37 ◦C for 15 min. The reaction was carried out in PBS. After 15 min, the
various concentrations (0.5, 0.25, 0.125 and 0.062 mM) of DSP was added to the
reaction mixture. The reactions were incubated at room temperature for 60 min and
quenched by adding 5 ml of 50 mM Tris-HCl, pH 7.6. Samples were electrophoresed
on a 15% SDS-PAGE, transfered onto nitrocellulose membrane and detected with
FGE or pFGE antiserum.
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2.4.14 Treatment with N-ethylmaleimide (NEM)
HT1080 cells were transiently transfected with pFGE and FGE or pFGE. After 24h
of transfection, cells were washed with PBS and incubated with 10 mM NEM
(Fluka)/PBS for 10 min at 37 ◦C. Controls were incubated with PBS without NEM.
After trypsinization, cells were harvested by centrifugation, washed once with PBS,
and lysed in PBS containing 10 mM NEM. Protein concentration of cell extracts
was determined by Bradford’s reagent (Bio-Rad). For Western blot analysis, equal
amounts of proteins were applied for SDS-PAGE under reducing and non-reducing
conditions (with and without 5% mercaptoethanol), transferred to nitrocellulose,
and probed with a mixture of pFGE and FGE antiserum and horseradish peroxidase-
conjugated goat anti-rabbit antibody as primary and secondary antibody, respec-
tively.
2.4.15 Indirect immunofluorescence
Cells were seeded on round coverslips in a 24-well plate 1-2 days in advance and
grown to 50-70% confluency. All the incubation steps given were performed by
filling the wells with 0.2 ml of the respective solution unless indicated otherwise.
Solutions were changed carefully for the cells should neither be washed away
nor become dry. The lid of the cell culture plate was closed during prolonged
incubations and upon application of the secondary, fluorescent antibody the samples
were protected from light.
Fixation with para-formaldehyde:
PFA reacts with nitrogen-containing groups and in effect crosslinks the proteins in
a cell.
3.7% para-formaldehyde (PFA):
The required amount of PFA was suspended in 1/5 of the final volume, mixed with
50 µl of 1 M NaOH/g PFA and dissolved by incubation at 60 ◦C for about 1 h. The
solution was stored for 1-2 weeks at 4 ◦C.
0.5% saponin-PBS:
10% stock solution, stored at -20 ◦C
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Protocol
Cells were washed once with PBS and fixed with 3.7% PFA for 20 min at room
temperature. After two washes with PBS, aldehyde groups were blocked by 50 mM
NH4Cl for 10 min at room temperature. The cells were washed twice with PBS
and permeabilised for 10 min at room temperature with 0.5% saponin in PBS. After
this step, all PBS solutions should contain 0.1% saponin. After permeabilization,
cells were wased once with PBS/saponin and incubated with primary antibody for
1hr/37 ◦C. Then cells were washed twice with PBS/saponin and incubated with 10%
goat serum in PBS. After incubation, cells were washed once with PBS/saponin and
incubated with secondary antibody coupled with flurochrome for 30 min at 37 ◦C.
Then cells were washed twice with PBS and left them in water. The coverslips were
carefully taken out with a forceps, dried from excess water and adhered upside-
down to a drop of DAKO mounting medium on a glass slide. The slides were
protected from light to dry overnight and sealed with nail-polish the next day.
Indirect immunofluoresence of fibroblasts and HT1080 cells
To detect endogenous expression of pFGE, the human skin fibroblast cells were
grown on cover slips for two days. For recombinant expression of pFGE, the
HT1080 cells were grown on cover slips and cotransfected with pBI-pFGE.HA and
rtTA using Lipofectamine 2000 (Invitrogen) as described above. After 36hr of
Transfection, the cells were analysed for indirect immunofluoresence as described
above. For the colocalization studies, rabbit pFGE-His antiserum and monoclonal
antibodies against HA tag (Covance, Princeton) were used as primary antibodies.
The endoplasmic reticulum marker protein, Protein Disulfide Isomerase (PDI) was
detected with a monoclonal antibody of different subtypes (IgG2A, Stressgen). The
primary antibodies were detected with isotype specific goat secondary antibodies
coupled to Cy2 or Cy3 (Molecular Probes), respectively. Confocal images were taken
on Leica TCS SP2 AOBS laser scan microscope.
2.4.16 Immunoelectron microscopy
For immunoelectron microscopy, ultrathin cryosections were prepared as described
[54]. For immunolabeling, sections were incubated with a polyclonal antibody
against pFGE (1:25) for 30 min followed by a 20-min incubation with protein A-gold
(10 nm). After washing steps, sections were fixed for 5 min with 1% glutaraldehyde.
Sections were then quenched with glycine and blocked with bovine serum albumin
before they were incubated with monoclonal antibodies against protein disulfide
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isomerase (1:30, StressGen Biotechnologies) or LAMP I (1:25, Hybridoma Bank)
followed by a bridge antibody for 30 min (rabbit anti-mouse) and protein A-gold (5
nm) for 20 min. Sections were contrasted with uranyl acetate/methyl-cellulose for
10 min on ice, embedded in the same solution, and examined with a Philips CM120
electron microscope.
2.4.17 EndoH / PNGase treatment
Stably expressing pFGE.His HT1080 cells were plated in 6 cm dishes at 50%
confluence. Cells were grown till the confluence and medium was changed with
fresh medium. After 48 h in fresh medium, cells and medium were collected for
partial purification of FGE-His by chromatography on Ni-NTA agarose under native
conditions according to the manufacturer’s protocol (Qiagen). Instead of using
imidazole, protein was eluted by boiling the Ni-agarose beads in 0.1% SDS/0.1 M -
mercaptoethanol at 95 ◦C for 5 min. The eluate was used for PNGase (with addition
of Triton X-100) and EndoH treatment as recommended by the manufacturer (Roche
Applied Science).
2.4.18 Limited proteolysis and protein sequence analysis
pFGE-His purified from the secretion of HT1080 cells was treated with thermolysin
or elastase in phosphate-buffered saline at a protein to protease ratio of 25:1
(w/w) for up to 24 h at room temperature. The reaction was stopped by adding
SDS-PAGE loading buffer and heating at 95 ◦C. The digests were separated by
SDS-PAGE, followed by Coomassie Blue staining. For N-terminal sequencing, the
proteolytic fragments were resolved by SDS-PAGE, blotted onto a polyvinylidene
difluoride membrane (Schleicher and Schuell, Germany), stained with Coomassie
Blue, excised from the membrane and subjected to Edman degradation on a Procise
cLC sequenator (Applied Biosystems).
2.4.19 Reductive carbamidomethylation and tryptic digestion
Purified pFGE-His (20-200 µg) was dried, solubilized in 45 µl of 8 M urea, 0.4 M
ammonium bicarbonate, pH 8.6 (buffer U), and reduced with 5 µl of100 mM DTT in
buffer U at 56 ◦C for 1 h. Cysteines were carbamidomethylated by incubation with 5
µl of 300 mM iodoacetamide in buffer U in the dark at 25 ◦C for 30 min. Reduction
and carbamidomethylation were repeated (adding 7.5 µl of 100 mM DTT and 5 µl
of 300 mM iodoacetamide, respectively) and the excess of iodoacetamide quenched
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with 2.5 µl of 100 mM DTT. The pH was adjusted to about 2 by adding 130 µl2%
trifluoroacetic acid/water, and the enzyme was purified on a C4 reversed-phase
column (Aquapore BU-300 7-micron 20 x 2.1 mm) applying a 0-90% acetonitrile
gradient in 0.1% trifluoroacetic acid (1.5% per min). The pFGE-His containing
fraction was lyophilized, solubilized in 25 µl buffer U, diluted to 100 µl with water,
and digested with trypsin (2% w/w) at 37 ◦C overnight. For the identification of
disulfide bridges, reduction and carbamidomethylation were omitted, and native
pFGE was directly digested with trypsin (at 10% w/w). After digestion the peptides
were purified in aliquots, corresponding to 20 µg of pFGE, on a microbore C18
reverse phase column (C18 PepMap100 1 x 150 mm, Dionex) applying a 0-63%
acetonitrile gradient in 0.1% trifluoroacetic acid (1.0% per min). All reverse phase
purifications were performed on a SMART system (Amersham Biosciences).
2.4.20 Mass spectrometry and Edman sequencing
For the analysis of cysteine modifications and the oligosaccharide sidechain struc-
ture, tryptic peptides of pFGE were subjected to matrix-assisted laser desorption
ionization time of flight mass spectrometry (MALDI-TOF MS) using a Reflex III
(Bruker Daltonik, Germany) and dihydroxybenzoic acid as matrix. In order to prove
the identity of cysteine or oligosaccharide containing peptides selected fractions
were subjected to edman sequencing (Procise cLC, Applied Biosystems).
2.4.21 Metabolic labelling and immunoprecipitation
Normal human skin fibroblast cells were grown to near confluence in 30 mm dishes,
cells were starved in 2 ml of Methionine and cysteine-free DMEM for 1h, pulsed
for 6 hours with 2ml of medium containing 50 µci of 35S-labelled Methionine and
Cysteine supplemented with 10% dialysed fetal calf serum and harvested or washed
with cold PBS and cultured in 2ml of chase medium (DMEM containing Methionine,
Cysteine and 10% FCS) for 16h. Medium was collected from all the plates and
cells were harvested by scrapping. Immunoprecipitation of pFGE from cells and
medium was performed with pFGE anti-serum as described earlier [55]. Pellets
were finally solubilized and subjected to SDS-PAGE and fluorography. Densitometric
quantification of pFGE was done using a Bio-Imaging Analyser, FUJI.
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2.4.22 Photocrosslinking
For photoaffinity labelling, a benzophenone labelled peptide was synthesised corre-
sponding to Arysulfatase A (residues 59-81) with an additional -biotinylated lysine
residue at the N-terminus and a benzoyl phenylalanine at position 77 instead of
leucine. The reaction mixture, containing 50µM of benzophenone labelled peptide,
1µM of each pFGE-His and bovine serum albumin or FGE-His was irradiated for 30
minutes on ice with an Ultra tech 400W halogen metal vapor lamp (Osram) [54].
The photoadducts were analysed by western blotting using the His tag or biotin
monoclonal antibody as primary antibody and HRP conjugated goat anti- mouse
antibody as secondary antibody.
2.4.23 Co-immunoprecipitation
Transfected cells were removed from dishes by scrapping, pelleted by centrifugation
and lysed by ultrasonication in PBS containing protease inhibitors (protein inhibitor
cocktail, Sigma). The cell lysates were spun down at 125,000 Xg for 30 min. The
supernatent was incubated with respective antibody for overnight at 4 ◦C. To the
suspension prewashed 10% StaphA (Pansorbin) was added, and the sample was
incubated for 1 hr at 4 ◦C. After centrifugation of the StaphA, antibody-antigen
complex was washed five times with PBS, boiled in 1x laemmli buffer, and separated
by 15% SDS-PAGE under reducing conditions. For immunoblotting, gels were trans-
fered onto nitrocellulose membranes, incubated with primary antibodies followed
by peroxidase-conjugated anti-rabbit or anti-mouse antibody, and developed by
chemiluminescence.
Chapter 3
Results
3.1 Molecular characterization of pFGE, the paralog
of FGE
Sequence comparisons led to the discovery of a paralogue of SUMF1 in the ver-
tebrate genomes, named SUMF2. SUMF2 encoded pFGE shares 47% sequence
identity and 62% similarity with SUMF1 encoded FGE (Fig 3.1). The region between
Alignment:       human FGE  –  human pFGE
FGE     89  SKMVPIPAGVFTMGTDDPQIKQDGEAPARRVTIDAFYMDAYEVSNTEFEKFVNSTGYLTE  148
            + MV +  G F MGT+ P   +DGE P R  T+  F +D + V+N +F  FV    Y TE
pFGE    28  TSMVQLQGGRFLMGTNSPD-SRDGEGPVREATVKPFAIDIFPVTNKDFRDFVREKKYRTE   86
FGE    149  AEKFGDSFVFEGMLSEQVKTNIQQAVAAAPWWLPVKGANWRHPEGPDSTILHRPDHPVLH  208
            AE FG SFVFE  +S++++    Q + +  WWLPV+ A WR P GP S I  R +HPVLH
pFGE    87  AEMFGWSFVFEDFVSDELRNKATQPMKSVLWWLPVEKAFWRQPAGPGSGIRERLEHPVLH  146
FGE    209  VSWNDAVAYCTWAGKRLPTEAEWEYSCRGGLHNRLFPWGNKLQPKGQHYANIWQGEFPVT  268
            VSWNDA AYC W GKRLPTE EWE++ RGGL  +++PWGN  QP   +  N+WQG+FP
pFGE   147  VSWNDARAYCAWRGKRLPTEEEWEFAARGGLKGQVYPWGNWFQP---NRTNLWQGKFPKG  203
FGE    269  NTGEDGFQGTAPVDAFP-PNGYGLYNIVGNAWEWTSDWWTVHHSVEETLNPKGPPSGKDR  327
            +  EDGF G +PV+AFP  N YGLY+++GN WEWT+   + + + E+ +          R
pFGE   204  DKAEDGFHGVSPVNAFPAQNNYGLYDLLGNVWEWTA---SPYQAAEQDM----------R  250
FGE    328  VKKGGSYM--CHRSYCYRYRCAARSQNTPDSSASNLGFRCAAD                   368
            V +G S++     S  +R R   R  NTPDS++ NLGFRCAAD
pFGE   251  VLRGASWIDTADGSANHRARVTTRMGNTPDSASDNLGFRCAAD                   293
Score =  269 bits (687), Expect = 9e-71
Identities = 134/283 (47%), Positives = 178/283 (62%), Gaps = 20/283 (7%)
Figure 3.1. Sequence alignment of human-FGE and human-pFGE
The letters in between sequences indicat s, identities in FGE and pFGE. The plus symbol
indicates, similarities in FGE and pFGE.
aminoacids 303 and 351 of the human FGE differs from the corresponding region of
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human pFGE. SUMF1 is conserved from bacteria to man, whereas SUMF2 evolved
later and is present only in present in deuterostomia. [41, 51].
3.1.1 Cloning of human pFGE encoding cDNA (SUMF2)
Total RNA was prepared from human fibroblasts and reverse transcribed to cDNA
by reverse transcriptase using an oligo (dT) primer or a SUMF2-specific primer (see
Methods). The first strand cDNA was amplified by PCR using the SUMF2 specific
forward and reverse primers. The PCR products were cloned directly into the pCR4-
TOPO vector. By sequencing multiples of the cloned PCR products, which had
been obtained from various individuals and from independent reverse transcriptase
and PCR reactions, the cDNA sequence coding for pFGE (906 bp from start to
stop codon) was established. The sequence corresponds to GenBankTM entry
NM 015411 but deviates in one position(87C>T). This change is a silent mutation
in the third position of the serine 29 codon and may reflect a polymorphism.
3.1.2 Expression of SUMF2
Figure 3.2. Expression of pFGE (A), FGE (B) and β-actin (C) in human tissues
Northern blot analysis of polyA+ RNA from human tissues. Very similar expression patterns
were obtained when using probes hybridizing either in the coding region, as shown here, or in
the non-conserved 3’ untranslated region (not shown).
A human multi tissue Northern blot was hybridized with 32P-labelled cDNA
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probes covering the entire coding regions of pFGE or FGE, respectively, and a
β-actin cDNA probe as a control for RNA loading. The results show, a single
transcript of 2.0-2.1 kb is detectable by Northern blot analysis of polyA+ RNA
from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas (Fig
3.2.A). The expression pattern compares well to that of SUMF1 (Fig 3.2.B), the
relative ratio of SUMF2 over SUMF1 varying between 0.5 in heart and 1.4 in brain
and pancreas. Relative to β-actin RNA (Fig 3.2.C) the abundance of SUMF2 RNA
varies by one order of magnitude, being highest in pancreas and kidney and lowest
in brain. Basically the same result, as shown in Fig.1, was obtained when using
probes hybridizing in the 3’ UTR regions of SUMF1 or SUMF2 mRNA, where the
two sequences show no similarity (not shown).
3.1.3 Subcellular localization of pFGE
Figure 3.3. Subcellular localization of pFGE-HA in HT-1080 cells.
After fixation and permeabilization the proteindisulfide isomerase was detected with a monoclonal
IgG2A antibody (green, A) and GM130 (green, D) with a rabbit antiserum. The HA-tag of pFGE
(red, B and E) with a monoclonal IgG1 antibody. The merge reveals co localization of PDI or
GM130 and pFGE in yellow (C, F)
pFGE with a C-terminal HA- or His-tag was transiently expressed in the human
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HT-1080 sarcoma cell line. pFGE colocalized with proteindisulfide isomerase, a
lumenal protein of the endoplasmic reticulum (Fig 3.3, A-C). In some cells as the
one shown in Fig 3.3, a fraction of pFGE was associated with perinuclear structures
devoid of proteindisulfide isomerase. This structure is enriched in the Golgi marker
protein GM130 (Fig 3.3), D-F). This indicates that recombinant pFGE is localized
in the endoplasmic reticulum. In some cells, however it accumulates in detectable
amounts also in the Golgi apparatus. Immunoelectronmicroscopy confirmed the
localization of pFGE in the endoplasmic reticulum where it colocalizes with protein
disulfide isomerase and in the Golgi stack (Fig 3.4). A sparse labelling for pFGE was
observed in structures enriched in the endosomal / lysosomal marker LAMP I.
Figure 3.4. Localization of pFGE-His in HT-1080 cells by immunoelectron microscopy
After fixation and cryosectioning, pFGE was detected with a rabbit antiserum against pFGE and
protein A-gold (10 nm). A shows double labeling with the endoplasmic reticulum marker protein
disulfide isomerase (5 nm gold), and B shows double labeling with the endosome/lysosome
marker LAMP I (5 nm gold). ER, GApp, and MVB designate endoplasmic reticulum, Golgi
apparatus, and multivesicular bodies, respectively. The scale bar corresponds to 100 nm.
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3.1.4 Secretion of pFGE-His by HT-1080 cells
Overexpressed pFGE-His, is only transient by being retained in the endoplasmic
reticulum. In HT-1080 cells most of the pFGE-His that was synthesized over a period
of 2 days (93% of total) was secreted. Cellular pFGE was kept at a rather constant
level (Fig 3.5).
Figure 3.5. Secretion of pFGE-His in HT-1080 cells
HT-1080 cells stably expressing pFGE-His were grown to half confluency. At time zero fresh
medium was added and the cells were harvested 0, 12, 24, 36 and 48 h of culture. pFGE was
quantified in equal aliquots of cell extracts (C) and media(M) by Western blot using a monoclonal
antibody against the His-tag (inset). The amount of intracellular and secreted pFGE-His per mg
cell protein was determined by calibration of the Western blot with known amounts of purified
pFGE-His and refered to total cell protein.
3.1.5 Analysis of N-glycosylation
pFGE contains a single potential N-glycosylation site at Asn 191. The intracellular
32 kDa pFGE-His was sensitive to endoglucosaminidase H and PNGaseF. Both
endoglycosidases decreased the apparent molecular size of the intracellular pFGE
by 2.5 kDa (Fig 3.6), indicating that intracellular pFGE contains a high-mannose (or
hybride) type oligosaccharide. The secreted pFGE is represented by a 31.5 and 32.5
kDa form. Both are converted into a 29.5 kDa polypeptide by PNGaseF, indicating
that the two forms arise from heterogenous N-glycosylation. The 31.5 kDa form is
sensitive to endoglucosamidase H, while the 32.5 kDa form is resistant (Fig 3.6).
This indicates that the 31.5kDa form contains a high mannose type oligosaccha-
ride, while the 32.5kDa form contains a complex type oligosaccharide. MALDI-
TOF analysis of the N-glycosylated tryptic peptide 179-192 of secreted pFGE-His
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confirmed the heterogenous glycosylation at Asn 191. The oligosaccharide mixture
was composed of 11 different species (Fig 3.8). They all belonged to the hybride or
complex type with up to 5 N-acetylhexosamine, six hexose, one sialic acid and one
fucose residue per oligosaccharide and masses ranging from 1768 to 2424 Da (Fig
3.7).
Figure 3.6. N-Glycosylation of intracellular and secreted pFGE-His
Cell extracts and secretions of HT-1080 cells expressing pFGE were treated with
endoglucosaminidase H (Endo H) or N-glycosidase I (PNGase), separated by SDS-PAGE and
detected by Western blot using anti-His antibodies. The filled arrows point to the glycosylated,
the open arrows to the deglycosylated pFGE forms
Figure 3.7. Complex type structure of the oligosaccharide side chain at aspargine 191 of
secreted pFGE, containing 5 N-acetylhexosamine, six hexose, one sialic acid and one fucose
residue per oligosaccharide
3.1.6 Large scale purification of pFGE-His
For purification of pFGE-His, the medium collected from HT1080 cells stably ex-
pressing pFGE-His was used as a starting material. The cells were grown to
near confluency in normal growth medium. The medium was collected every
48h, cleared by spinning, and subjected to ammonium sulfate precipitation (see
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Figure 3.8. N-Glycosylation secreted pFGE-His
N-glycosylated tryptic peptide 179-192 of secreted pFGE was purified by reverse-phase
chromatography and analyzed by MALDI-TOF MS. A series of 11 different mass signals was
found corresponding to peptide 179-192. The total mass of glycopeptide is 4172 Da.
Methods). The precipitate was reconstituted and dialyzed in Ni-NTA lysis buffer.
The dialysed material was cleared by spinning and applied to Ni-NTA affinity
chromatography (Fig 3.9).
Peak fractions were pooled and dialyzed against buffer A (see Methods). The
dialyzed protein was loaded to MonoQ anion exchange chromatography in contrast
to FGE, the pFGE-His protein was not bound to the column at pH 8. It was recovered
in the flow-through and other contaminants were bound to the column (Fig 3.10).
Flow through fractions were pooled, concentrated and dialyzed against Buffer A.
Analytical size-exclusion chromatography of the purified pFGE-His protein revealed
its homogeneity (Fig 3.11). From 1 liter of medium 8mg of pFGE-His could be
purified. On SDS gels pFGE-His protein appeared in two molecular forms (Fig 3.10).
The larger 32.5-KDa and smaller 31.5-KDa forms corresponded to full length pFGE
with alanine 27 at its N terminus, as analyzed by Edman Sequencing. However both
forms are distinguished by different glycosylation pattern (Fig 3.6).
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Figure 3.9. Ni-NTA purified pFGE-His
Ammonium sulfate precipitated pFGE-His medium was passed through Ni-NTA -agarose and
the fractions were run on a 15% SDS polyacrylamide gel. Staining was with Coomassie Brillant
Blue. The two different size of 32.5 and 31.5-KDa point to the differentially glycosylated forms
of pFGE. ∗ indicates bovine serum albumin from growth medium.
Figure 3.10. SDS-PAGE of fractions collected from MonoQ chromatography
Material eluted from Ni-NTA further purified by MonoQ chromatography . Aliquots of the
fractions were separated by 15% SDS polyacrylamide gel. Separated proteins were visualized
with Coomassie Brilliant Blue staining.
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Figure 3.11. Gel filtration chromatography
The flow-through fractions from MonoQ chromatography were pooled, concentrated and dialyzed
(see Methods). An aliquots of purified pFGE-His applied to a Superdex 200 gel-filtration column
that had been equilibrated in PBS and eluted isocratically with PBS. pFGE-His eluted as a single
peak and the fractions were run on a 15% SDS polyacrylamide gel and followed by staining with
Coomassie Brilliant Blue.
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3.1.7 Domain structure of pFGE-His
pFGE-His purified from the secretions of HT-1080 cells was incubated with elastase
or thermolysin at a pFGE/protease ratio of 25:1. Both proteases generated two
families of fragments of about 10-12 kDa and 22-24 kDa (Fig 3.12). The fragments
Figure 3.12. Limited proteolysis of pFGE-His by thermolysin and elastase
pFGE-His purified from secretions of HT-1080 cells was incubated for up to 24 h with
thermolysin or elastase at a FGE-protease ratio of 25:1(w/w). After separation by SDS-PAGE
the polypeptides were detected by staining with Coomassie blue. The molecular weights of pFGE
and the proteolytic fragments are indicated at the right. The scheme at the bottom shows the
locations of the sub domains 1, 2 and 3 together with the residue numbers defining the N-
and C- termini of mature pFGE and its sub domains. The arrows indicate the two proteolytic
cleavage sites of thermolysin N-terminal of threonine 109 and valine 115, as determined by
Edman sequencing.
generated by thermolysin were subjected to N-terminal amino acid sequencing. The
10-12 kDa fragments represent the amino terminus of mature pFGE starting with
residue 27, while the 22-24kDa fragments start with threonine 109 or with valine
115. Sequence comparison has revealed three subdomains in pFGE [42] (Fig 3.12
bottom). The thermolysin cleavage sites are located in the linker region between
subdomain 1 and 2, which extends from serine 93 to leucine 116.
3.1.8 Disulfide bridges of pFGE-His
To examine for a possible disulfide bonding of the two existing cysteine residues in
pFGE (at positions 156 and 290), pFGE-His purified from the secretions was first
reacted with NEM to modify free cysteine residues and then subjected to reductive
carbamidomethylation in the presence of urea to modify disulfide bonded cysteines.
After digestion with trypsin, the peptides were separated by reversed phase HPLC
on a C18 matrix and characterized by MALDI-TOF and N-terminal amino acid
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sequencing. The two cysteine-containing tryptic peptides (154-159 and 290-303)
were exclusively recovered as carbamidomethylated derivatives, indicating that
cysteine 156 and cysteine 290 are disulfide bonded in pFGE. In fact, when pFGE was
subjected to carbamidomethylation in the presence of urea without prior reduction
and then digested with trypsin, the two tryptic peptides 154-159 and 290-303 were
found to be connected by a disulfide bond. As non-reduced pFGE migrates in SDS-
PAGE as a monomer (not shown) cysteine 156 and 290 form an intramolecular and
not an intermolecular disulfide bond.
3.1.9 Generation and characterization of antisera against
pFGE-His
To allow for detection of endogenous pFGE, we wanted to generate antisera against
pFGE-His which was purified from secretions. A rabbit was immunized with purified
pFGE-His using stimune adjuvant (Cedi Diagnostics B.V). To screen high titer
antibodies, the rabbit antisera was regularly monitored by immunoprecipitation of
purified pFGE-His. The degree of immunoprecipitation of purified pFGE-His was
not changed between bleed 3 and bleed 4 antiserum (Fig 3.13). Hence, the rabbit
Figure 3.13. Titration of pFGE antisera by Immunoprecipitation
The rabbit sera were diluted to 1:5, 1:15, 1:50, and 1:150 in PBS and incubated with purified
pFGE-His. The mixture was precipitated by Pansorbin (see Methods). The precipitant was
resolved on SDS-PAGE and transfered to nitrocellulose and followed by probed with monoclonal
antibody against His-tag.
was sacrificed to collect blood after 3 booster injection (see Methods). pFGE is
highly similar to FGE, therefore it was essential to check whether pFGE antisera
could precipitate recombinant FGE. The results show that pFGE antiserum could
precipitate recombinant pFGE but not recombinant FGE (Fig 3.25 and 3.26). Next
we analyzed the sensitivity and cross-reactivity of pFGE antiserum towards purified
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Figure 3.14. Sensitivity and cross-rectivity of pFGE antiserum
Various amounts of purified pFGE-His and purified FGE-His were run on a SDS-PAGE and
followed by immunodetection with pFGE antiserum (1:2500 dilution).
Figure 3.15. Immunoprecipitation of endogenous pFGE
The cell extracts of human skin fibroblast or MSD fibroblast were immunoprecipitated with
pFGE antiserum. The presence of endogenous pFGE was revealed by immunoblotting with
pFGE antiserum. ? indicates the heavy chain of pFGE antibody.
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pFGE-His and FGE-His, respectively. This experiments reveal that pFGE antiserum
could detect 30 ng of purified pFGE-His. Nevertheless it weakly cross-reacted with
purified FGE (Fig 3.14). Above experiment was repeated with FGE antiserum
where in FGE antiserum exclusively reacts with FGE.
In an attempt to check whether pFGE antiserum was able to precipitate
endogenous pFGE, the extracts of human skin fibroblast cells or MSD fibroblasts
were subjected to immunoprecipitation with pFGE antiserum. The presence of
endogenous pFGE was detected by immunobloting with pFGE antiserum (Fig
3.15). However, to detect efficiently enogenous pFGE we had to start with ∼2mg of
cell extracts. In a control experiment, preimmmune serum replaced pFGE antiserum
which failed to precipitate specifically endogenous pFGE (data not shown).
pFGE antiserum allowed us to precipitate the endogenous pFGE, therefore we
were interested to know whether this antiserum is suitable for immunofluoresence
microscopy. The experiments demonstrate that pFGE antiserum was able to detect
endogenous pFGE (Fig 3.18, B and E).
3.1.10 Generation and characterization of monoclonal
antibodies against pFGE-His
We have learnt from our earlier experiments that pFGE antiserum could be used for
immunofluoresence and immunoprecipitation studies to detect specifically pFGE.
Albeit, it weakly cross-reacts with FGE on western blot. To circumvent this problem
again we raised polyclonal antibodies against purified pFGE-His in rabbit. Invari-
ably, we found that this antiserum also cross-reacts with FGE in western blot.
In order to have specific antibody against pFGE, we intended to generate mon-
oclonal antibody against purified pFGE-His. For this we had sent our purified
pFGE-His to Transkaryotic Therapies, Inc (cambridge, MA) to make hybridoma.
Supernatants from hybridomas were screened in our lab by western blot, im-
munoprecipitation and immunofluoresence studies. It should be noted that all
the screening experiments were carried out with purified pFGE-His or cells ex-
pressing His-tagged pFGE. Highly reactive best hybridoma clones were chosen in
among 100 different hybridoma clones. For these clones, ascites were produced to
have concentrated monoclonal pFGE antibodies. Finally we investigated all these
monoclonal antibodies for many purposes. Surprisingly we noticed that all these
monoclonal antibodies recognize only His-tagged intracellular and purified pFGE,
but not untagged intracellular pFGE. Moreover they cross-react with intracellular
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His-tagged FGE but not purified His-tagged FGE (Fig 3.16,3.17).
Figure 3.16. Cross-reactivity of pFGE monoclonal antibodies
Extracts from HT1080 cells expressing pFGE-His or FGE-His+pFGE were loaded on SDS-PAGE
including purified pFGE-His as a control. After transferring to nitrocellulose membrane, the blot
was probed with mixture of three monoclonal antibodies of pFGE-His (Blot.1). In lane 4 and
5 untagged pFGE was not detected by monoclonal antibodies but they recognized His-tagged
pFGE (lane1-3) and intracellular His-tagged FGE (lane 4 and 5). The blot.1 was re-probed with
pFGE antiserum in which untagged pFGE was detected by pFGE antiserum.
To verify this observation, we performed immunofluoresence using these an-
tibodies. This also suggested that pFGE monoclonal antibodies recognize His-
tagged pFGE but not untagged pFGE. And they were not sensitive enough to
detect endogenous pFGE in human skin fibroblasts either by immunofluoresence or
immunoprecipitation studies. Taken together all these data support that monoclonal
antibodies were likely raised against epitopes that include that His-tag of pFGE-His.
This is likely to explain their cross reactivity with FGE-His.
Figure 3.17. Sensitivity and cross-rectivity of monoclonal pFGE antibodies
Various amounts of purified pFGE-His and purified FGE-His were run on SDS-PAGE and followed
by immunodetection with pFGE monoclonal antibody.
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3.1.11 Localization and secretion of endogenous pFGE
When fibroblasts fixed with paraformaldehyde and permeabilized with saponin
were reacted with anti pFGE serum, pFGE was detectable in the endoplasmic
reticulum, where it colocalized with protein disulfide isomerase (Fig 3.18, A-C).
Association with the Golgi, as observed for overexpressed pFGE (Fig 3.3, D-F), was
Figure 3.18. Subcellular localization of endogenous pFGE in human skin fibroblasts.
After fixation and permeabilization the proteindisulfide isomerase was detected with a monoclonal
IgG2A antibody (green, A) and GM130 (green, D) with a monoclonal IgG1 antibody. The
endogenous pFGE (red, B and E) was detected with a rabbit antiserum. The merge reveals
colocalization of PDI and pFGE in yellow (C).There is no colocalization of endogenous pFGE
with the Golgi marker GM130 (F).
not detectable for endogenous pFGE (Fig 3.18, D-F).
To follow biosynthesis and possible secretion of endogenous pFGE, human skin
fibroblasts were metabolically labelled for 6 h with 35S- methionine. After labelling,
the cells were either harvested or subjected to a 16 h chase in 35S-methionine-free
medium. pFGE was immuno-precipitated from extracts of the cells and media,
separated by SDS-PAGE and visualized by phosphoimaging (Fig 3.19). pFGE was
synthesized as a 32 kDa polypeptide that remained stable during the 16 h chase
period. After the chase for 16 h, a small amount (less than 13%) was recovered in
the secretions as 31.5 and 32.5 kDa forms. This indicates that a small fraction of
endogenous pFGE escapes retention in the endoplasmic reticulum. Heterogeneous
processing of the N-linked oligosaccharide in the secretory pathway is likely to give
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Figure 3.19. Biosynthesis and secretion of endogenous pFGE
pFGE was immunoprecipitated from the cells and media of human skin fibroblast that had been
labelled for 6 h and harvested either directly after metabolic labelling or after a chase for 16 h.
The arrows indicate the intracellular 32 kDa pFGE form (left) and the secreted 31.5 and 32.5
kDa forms (right).
rise to the two 31.5 and 32.5 KDa pFGE forms in the secretions, as has been shown
for recombinant pFGE (Fig 3.6).
3.1.12 pFGE lacks FGly-generating activity
pFGE is the paralog of FGE, which has FGly generating activity. The generation
of FGly residue is readily detectable with the help of the 23mer peptide P23.
This peptide corresponds to arylsulfatase A 60-80, with an additional N-acetylated
methionine and a C-amidated serine residue to protect its N- and C-terminus,
respectively[41]. It contains the cysteine residue to be modified and neighbouring
residues, which are essential for the FGly formation. The FGE activity in extracts of
HT-1080 cells transiently expressing pFGE-His was in the range of non-transfected
HT-1080 cells, whereas FGE activity in extracts of cells expressing a comparable
amount of FGE-His was more than 20-fold increased (Fig 3.20). When purified
pFGE-His was incubated with P23 the peptide under conditions that allow quanti-
tative modification of the cysteine residue by purified FGE-His, no FGly formation
was detectable. Increasing or decreasing the amount of pFGE-His did not result in
FGly-formation.
The human genome predicts 17 sulfatases of which 16 have been shown to
be expressed in various tissues. To test whether pFGE can modify any of them,
we synthesized peptides derived from all 16 sulfatases as N-acetylated 23-mers
comprising residues -10 to +11, with the critical cysteine in position 0 and a C-
terminal serine amide. These peptides were used as pFGE or FGE substrates at
200nM concentration, this is about 15-fold above the half-saturating concentration
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Figure 3.20. FGE activity in HT-1080 cells expressing pFGE-His or FGE-His
The upper panel shows the Western blot detection of pFGE-His and FGE-His in the cell extracts
with a monoclonal antibody against the His tag. The lower panel shows the FGly-generating
activity in the cell extracts determined in vitro with the P23 peptide as substrate. Bar 1,
non-transfected HT-1080 cells; bars 2 and 3, cells transiently expressing pFGE-His or FGE-His,
respectively.
determined for P23 [41]. As shown in Table 3.1, FGE was able to generate FGly in
all tested peptides. But none of them were modified by pFGE. This indicates that
pFGE lacks FGly-generating activity.
3.1.13 Recombinant pFGE impairs sulfatase activity
In vivo, the activity of FGE can be a limiting factor for the synthesis of catalytically
active sulfatases. This becomes apparent when sulfatases are overexpressed. The
yield of sulfatase activity is increased by simultaneous overexpression of FGE [41,
51]. When FGE was transiently coexpressed with steroid sulfatase in HT-1080 cells,
the activity of steroid sulfatase increased about 2-fold. In contrast, coexpression of
pFGE reduced the sulfatase activity by about half (Fig 3.21). The inhibitory effect
may indicate that pFGE competes with the endogenous FGE for modification of
the recombinant steroid sulfatase. In line with this assumption, we observed that
coexpression of pFGE and FGE abolished the stimulatory effect of FGE on steroid
sulfatase activity (Fig 3.21). Control experiments verified that both tagged and
non-tagged pFGE fail to activate steroid sulfatase (not shown). A similar result was
observed when pFGE-His and galactose 6-sulfatase were stably coexpressed in HT-
1080 cells. Coexpression of pFGE-His reduced the specific activity of the galactose
6-sulfatase by 20 % , whereas coexpression of FGE increased the specific activity
of galactose-6-sulfatase more than 100-fold (see in the next section Fig 3.28). The
different efficiencies of FGE-mediated activation and pFGE-mediated inhibition in
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Table 3.1. FGE-mediated turnover of peptides derived from human sulfatases
The indicated synthetic peptides are derived from the 16 human sulfatases predicted by the
human genome, with the homologous amino acid positions given in the peptide name. All
peptides are N-terminally acetylated and carry a serine amide in the C-terminal position as a
protective group against peptidases. Two peptides (P23 and I2S) carry a point mutation in
the first position (F59M and F74L, respectively) in order to avoid coincidence of their masses
with those of others. The core FGly modification motif [29] of all peptides is underlined. The
cysteine to be modified and its 1 neighbor are boldface. The peptides are grouped according
to the nature of this 1 residue (threonine, serine, cysteine, or alanine). 6 pmol of each peptide
were incubated for 30 min under standard assay conditions (see ”Materials and Methods”) with
1ng of FGE, purified from HT1080 secretions. The FGly modification of the peptides by FGE is
given as absolute (pmol/h) and relative activity (percentage of P23 turnover).
the two experiments are explained by the much higher expression of galactose 6-
sulfatase, as compared with that of steroid sulfatase. This by far exceeded the FGly-
generating capacity of endogenous FGE, thus leaving large amounts of unmodified
galactose 6-sulfatase as a substrate for the recombinant FGE. Accordingly, the lower
inhibitory effect of coexpressed pFGE on galactose 6-sulfatase may be due to the
high expression level of these sulfatases, clearly exceeding that of pFGE. Taken
together, these data support the view that pFGE has no FGly-generating activity
toward the three sulfatases tested (arylsulfatase A, steroid sulfatase, and galactose-
6-sulfatase). The inhibitory effect of pFGE in vivo on the formation of active
sulfatases suggests that pFGE can interfere with the activity of FGE on sulfatases. A
number of mechanisms are conceivable to explain the inhibitory effect of pFGE on
the generation of catalytically active sulfatases. Among them are binding of pFGE
to FGE or/and to sulfatases and thereby interfering with the modification of nascent
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Figure 3.21. pFGE-HA reduces and FGE-HA enhances the activity of steroid sulfatase.
In HT-1080 cells, steroid sulfatase (STS), pFGE-HA, and FGE-HA were transiently coexpressed
in the combinations indicated below the lanes. In the cell extracts, the expression of steroid
sulfatase, pFGE-HA, and FGE-HA was monitored by Western blotting using a rabbit antiserum
against steroid sulfatase and a monoclonal antibody against the HA tag (top). The activity of
steroid sulfatase, referred to total cell protein, is shown at the bottom. It should be noted that
the transfected cDNAs were located on two vectors, one vector coexpressing steroid sulfatase
and, where indicated, FGE-HA from a bidirectional promotor, and another vector expressing
pFGE-HA only (see ”Materials and Methods”).
sulfatase polypeptides by FGE.
3.1.14 Binding of pFGE to Sulfatases
Binding of FGE to sulfatases has been demonstrated in several experimental sys-
tems. When extracts of HT-1080 cells coexpressing FGE-His and galactose 6-
sulfatase are subjected to gel permeation chromatography, complexes of FGE and
galactose-6-sulfatase coelute(see in the next section Fig 3.26). In cells coexpressing
pFGE-His and galactose 6-sulfatase, we failed to observe complexes. pFGE-His and
galactose-6-sulfatase eluted as monomers of 20 and 55 kDa, respectively (Fig 3.22).
Photocrosslinking of pFGE-His to an arylsulfatase A peptide
(in cooperation with Andrea Preusser-Kunze)
A peptide representing arylsulfatase A residues 60-80, but carrying a p-benzoyl
phenylalanine (Bpa) at position 77 and a biotinylated lysine residue at the N
terminus, can be photocross-linked to FGE (Fig 3.23, lane 5). Replacing FGE by
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Figure 3.22. Galactose-6-sulfatase and pFGE-His do not coelute
The extracts of HT1080 cells expressing pFGE-His and galactose-6-sulfatse (Gal-6-S) were
chromatographed by Superdex-200 as described under ”Materials and Methods”. The fractions
were analyzed by immunobloting using a mixture of galactose-6-sulfatase and His-tag monoclonal
antibodies. Percentage of pFGE or Gal-6-S were calculated by quantifying the western blot
signals using densitometry.
pFGE, we also observed cross-linking of the peptide to pFGE, albeit at only one-
tenth of the efficiency observed for FGE-His (Fig 3.23, lane 1). Cross-linking was
specific as indicated by the inhibitory effect of a 2-fold excess of the arylsulfatase A
60-80 peptide P23 (Fig 3.23, lane 2) and by the lack of cross-link products when
bovine serum albumin (Fig 3.23, lane 4), ovalbumin, or ribonuclease were used as
acceptor proteins. When biotinylated ASA peptides with Bpa residues in position 62
or 66 were used, the cross-linking efficiency was further lowered and substitution
of the critical cysteine 69 by alanine reduced cross-linking to pFGE 10-fold.
3.1.15 Interaction of pFGE and FGE
While the results clearly demonstrate that pFGE and FGE have much in common
with respect to their expression pattern, localization and structural features. There-
fore we were interested to check whether pFGE interacts with FGE.
Biochemical approaches to study pFGE and FGE interaction
To determine whether pFGE forms intermolecular disulfide bridge with FGE, cells
expressing pFGE and FGE were treated N-ethyl maleimide to irreversibly modify
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Figure 3.23. Photocross-linking of pFGE-His to an arylsulfatase A peptide.
pFGE-His (lane 1-3), bovine serum albumin (lane4) or FGE-His (lane5), 1µM each, were
incubated with 50µM of a peptide corresponding to arylsulfatase A residues 59-81 with an
additional - biotinylated lysine residue at the N-terminus and a benzyl phenylalanine at position
77 instead of leucine 77. In lane 2 a twofold excess of P23, corresponding to arylsulfatase
residues 60-80 with additional N-acetylated methionine and a C- amidated serine residues at the
N- and C- terminus, was added. After irradiation with UV- light for 30min on ice, equal aliquots
of the samples were subjected to SDS-PAGE, transfer onto nitocellulose membrane and probed
with antibodies against biotin (upper panel) the His-tag (lower panel). The position of bovine
serum albumin, FGE and pFGE are indicated by arrows.
thiol groups. The cells were then lysed and extracts applied on 15% SDS polyacry-
lamide gels in reducing and non reducing conditions. After transfer to nitrocellulose
membrane, pFGE and FGE were identified by immunodetction with a mixture of
FGE and pFGE antiserum. The data show that under non reducing condition there
was no cross reacting material at the size expected for FGE-pFGE complexes.
We next addressed whether pFGE and FGE form non-covalent complexes, Ni-
agarose pull-down assay was performed using the extracts of HT1080 cells coex-
pressing pFGE-His and FGE. His-tagged pFGE was precipitated from the cell extracts
with Ni-NTA agarose. The precipitant was examined for the presence of FGE by
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Figure 3.24. Purified pFGE-His and FGE-His on gel permeation chromatography
Fig A, B: Purified FGE-His or pFGE-His was chromatographed on Superdex-200. Protein
fractions were analyzed by Western blot using a monoclonal antibody against His-tag. Fig
C: Purified pFGE-His and FGE-His were mixed in a 2:1 molar ratio and incubated at room
temperature for 30 minutes. The reaction was carried out in PBS at pH 7.4. Then the mixture
was passed through Superdex-200. Protein fractions were analyzed by Western blot using His-tag
monoclonal antibody.
Western blotting with FGE antiserum. Ni-NTA agarose pulled down pFGE-His and
did not coprecipitate FGE along with pFGE-His(not shown).
We failed to detect complexes of pFGE and FGE by demonstration of co-elution
during gel permeation chromatography, employing extracts of FGE-His and FGE
coexpressing cell lines (not shown). This observation is substantiated by the
same experiment was repeated with a mixture of purified FGE-His and pFGE-
His. Whereas pFGE-His and FGE-His get eluted as monomers of 25 and 45 kDa,
respectively (Fig 3.24).
Further we studied whether pFGE interacts with FGE in in vivo condition. To
demonstrate this, the cells transiently coexpressing FGE-His and pFGE-HA were
treated with the chemical cross-linker dithiobis (succinimidyl propionate) (DSP),
which has a fixed spacer arm of 12 A˚ and a disulfide bond that can be cleaved
with reducing agents. Cells were then lysed and the cell extracts were treated
with or without DTT to cleave the DSP cross-linker. The extracts were resolved
by SDS-PAGE and pFGE-HA and FGE-His were identified by immunoblotting with
monoclonal antibodies of HA- or His-tag. The results show that there was no
cross-linked adduct of pFGE and FGE, however, we observed FGE homodimer. In
parallel in vitro cross-linking was performed using a mixture of purified pFGE-His
and FGE-His. The cross-linked products were treated with or without DTT and
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Figure 3.25. Coimmunoprecipitation of pFGE and FGE
Fig A: HT1080 cells were transiently transfected with FGE or FGE and pFGE. The extracts from
these cells were immunoprecipiated with pFGE antiserum and immunoblotted with a mixture
of pFGE and FGE antiserum. It should be noted that the transfected cDNAs were located
on two vectors, one vector coexpressing FGE and pFGE from a bidirectional promoter, and
another vector expressing either pFGE or FGE only (see ”Materials and Methods”). Fig B:
HT1080 cells were transfected with pFGE or FGE and pFGE. The extracts from these cells were
immunoprecipiated with pFGE antiserum and immunoblotted with a mixture of pFGE and FGE
antiserum
separated on SDS-PAGE and immunodetected with monoclonal antibody of His-tag.
Again, no crosslinked products were obtained except FGE homodimer.
So far most of the biochemical approaches were done with using C-terminally
His or HA tagged pFGE or FGE. In order to exclude the possibility of C-terminal
His or HA tag interfering the interaction of pFGE and FGE, we performed coim-
munoprecipitation experiments using cells expressing untagged pFGE and FGE. The
protein extracts from these cells were immunoprecipitated by either pFGE or FGE
antiserum. The precipitant was resolved on 15% SDS-PAGE and immunoblotted
with a mixture of pFGE and FGE antiserum. The results demonstrate, neither pFGE
antiserum nor FGE antiserum immunoprecipitate the complex of pFGE and FGE.
However, pFGE antiserum or FGE antiserum could immunoprecipitate pFGE or FGE
alone, respectively (Fig 3.25). The above coimmunoprecipitation was repeated with
a mixture of purified pFGE-His and FGE-His. Invariably, there was no interaction
between pFGE and FGE observed.
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3.1.16 Interaction of pFGE and FGE in presence of Sulfatase
substrate
We could not observe direct interaction of pFGE and FGE through biochemical
approaches. Nevertheless we cannot exclude that pFGE and FGE interaction could
be substrate-dependent. To check this, we examined whether the addition of pFGE
to a mixture of FGE and its peptidic substrate P23 would inhibit the FGly formation.
pFGE added in an up to 300-fold molar excess over FGE had no effect on FGly
formation, neither at a low P23 concentration close to its Km (13 nM) nor at a
saturating P23 concentration (200 nM). Thus, in vitro pFGE has no inhibitory effect
on FGE activity toward peptidic substrates.
Binding of pFGE to either peptidic substrate or FGE may not inhibit the FGly
formation. To rule out this premise, we incubated pFGE and FGE in presence
of peptidic substrate P23. Then the mixture was subjected to gel permeation
chromatography. The elution profile reveals, pFGE do not co-purify with FGE in
presence of substrate peptide. It is possible that FGE might interact with pFGE
upon binding with substrate peptide. The transition state of the enzyme substrate
complex would last for a short time therefore we may not observe the interaction
of pFGE and FGE. The transition state can be stabilized by using mutant peptidic
substrate C69S-ASA (positions 65-80 with the critical cysteine 69 mutated to serine)
which can not be modified by FGE [41]. The above experiments was repeated with
this mutant peptidic substrate. This data also supported that apparently there was
no coelution of pFGE and FGE in presence of mutant peptidic substrate (not shown).
In parallel in vitro cross-linking was performed with a mixture of pFGE, FGE
and peptidic substrate or mutant peptidic substrate. Invariably there was no
crosslinked adducts were obtained except FGE homodimer. Taken together, all these
in vitro experiments confirmed that pFGE does not interact with FGE under variable
conditions.
To verify the in vivo interaction of pFGE and FGE in presence of sulfatase
substrate. We co-transfected HT1080 stably expressing arylsulfatase A with FGE and
pFGE. The protein extracts from these cells were immunoprecipitated with the pFGE
or FGE antiserum and immunoblotted with a mixture of pFGE and FGE antiserum.
Consistently, we found neither pFGE nor FGE antiserum precipitate the complex of
pFGE and FGE (Fig 3.26). However, pFGE or FGE antiserum could precipitate pFGE
or FGE alone, respectively.
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Figure 3.26. Coimmunoprecipitation of pFGE and FGE in presence of arylsulfatase A
Fig A: HT1080 cells stably overexpressing arylsulfatase A were transiently transfected with pFGE
or FGE and pFGE. The extracts from these cells were immunoprecipiated with pFGE antiserum
and immunoblotted with a mixture of pFGE and FGE antiserum. Fig B: HT1080 cells stably
overexpressing arylsulfatase A were transfected with FGE or FGE and pFGE. The extracts from
these cells were immunoprecipiated with pFGE antiserum and immunoblotted with a mixture of
pFGE and FGE antiserum
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3.2 Effect of FGE on sulfatases activitiy
Catalytically active recombinant sulfatases are needed for enzyme replacement
therapy of patients suffering from the deficiency of specific lysosomal sulfatases.
It was shown that endogenous FGE is limiting the synthesis of active recombinant
sulfatases[52, 18]. Therefore we studied the effect of over-expression of FGE on
sulfatase activity.
3.2.1 Establishing cell line and Transfection system
We examined steroid sulfatase activity (STS) in four different cell lines (CHO, BHK,
Cos-7 and HT1080) cotransfected with FGE-HA and STS. There was no significant
difference in STS activity between cells expressing STS together with or without
FGE-HA. The failure to detect a stimulatory effect of FGE-HA on STS activity may
be due to a low expression of STS which could be modified by endogenous FGE.
It is also possible that FGE-HA and STS do not efficiently reach the same cells.
Therefore we were seeking for a different experimental set up that allows efficient
coexpression of FGE-HA and STS in the same cells. This was achieved by using tet-
responsive expression vector pBI (Clontech), which allows regulated coexpression
of two cDNAs (STS and FGE-HA) from a bidirectional CMV promoter.
3.2.2 Coexpression of FGE-HA and steroid sulfatase in HT1080
cells
Using the above set up, we transiently transfected HT1080 cells with STS or STS
plus FGE-HA. The results show that FGE coexpression enhanced the activity of STS
about three fold. The activity of FGE was increased up to 22 fold (Fig 3.27). In
addition, we determined the activity of endogenous arylsulfatase A (ASA). But there
was no enhancing effect of FGE on ASA. These observations emphasize that the
endogenous FGE is sufficient to modify most of the recombinant STS. Thus, the
stimulatory effect of FGE on STS is rather low upto 3 fold, however it is consistent.
3.2.3 Expression of FGE-HA or pFGE-HA in HT1080-galactose-6-
sulfatase cells
To gain insight into the stimulatory effect of FGE on different sulfatase activity,
we transiently transfected FGE-HA or pFGE-HA into HT1080 cells stably expressing
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Figure 3.27. Coexpression of FGE-HA and steroid sulfatase
In HT1080 cells, steroid sulfatase (STS), FGE were transiently transfected in the combinations
indicated below the lanes. In the cell extracts, the expression of STS, FGE-HA was monitored
by western blot using a rabbit antiserum against STS and monoclonal antibody against the HA
tag. The activity of STS refered to total cell protein (bottom). The FGE activity was measured
after partial purification of cell extracts by MonoQ [41] and referred to total cell protein (top).
galactose-6-sulfatase. It should be noted that the surplus expression of galactose-
6-sulfatase in this stable cell line by far exceeded the FGly generating capacity of
endogenous FGE, thus leaving large amounts of unmodified galactose-6-sulfatase as
a substrate for the recombinat FGE-HA. To our surprise, the result shows that FGE-
HA expression enhanced the activity of galactose-6-sulfatase only 2.5 fold . There
was no effect of pFGE-HA on galactose-6-sulfatase (Table3.2). It is conceivable
that the expression of galactose-6-sulfatase and FGE-HA are not concomitant. Be-
cause galactose-6-sulfatase expression is stable and FGE-HA expression is transient.
Therefore we were not able to see high stimulatory effect of FGE on galactose-6-
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sulfatase activity.
Table 3.2. Transfection of FGE-HA or pFGE-HA in HT1080 galactose-6-sulfatase
Expression Galactose-6-Sulfatase Steroid sulfatase Arylsulfatase A
nmol/h*mg nmol/h*mg mu/mg
- 6.2 0.01 0.02
FGE-HA 15.3 0.01 0.02
pFGE-HA 4.0 0.01 0.02
Figure 3.28.
HT-1080 cells stably expressing galactose-6-sulfatase were transfected with pFGE-HA,
FGE-HA and STS in the combinations indicated below the chart. In the cell extracts, the
expression of steroid sulfatase, pFGE-HA, and FGE-HA was monitored by Western blotting
using a rabbit antiserum against steroid sulfatase and a monoclonal antibody against the
HA tag. The activity of steroid sulfatase and FGE, referred to total cell protein.
3.2.4 Coexpression of FGE-HA or pFGE-HA and STS in HT1080-
galactose-6-sulfatase cells
Our aim was to establish the cell line in which sulfatase stimulation by FGE could
be studied in more detail. For this we exploited a cell line stably overexpressing
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galactose-6-sulfatase. Using this cells, we transfected STS or STS plus FGE-HA and
STS plus pFGE-HA. Finally, we found FGE coexpression markedly enhanced STS
activity about 12 fold. As expected, pFGE-HA coexpression did not increase the
activity of STS rather it has very low inhibitory effect (Fig 3.28). Furthermore, we
determined activity of endogenous ASA activity in these cells. But, there was no
effect on ASA activity neither by FGE-HA or pFGE-HA.
3.2.5 Stable expression of FGE-His and galactose-6-sulfatase in
HT1080 cells
In order to achieve high stimulatory effect of FGE on galactose-6-sulfatase, we
stably transfected FGE-His into HT1080 galactose-6-sulfatase cells. In these cells,
specific activity of galactose-6-sulfatase increased more than 100 fold, whereas
coexpression of pFGE-His reduced specific activity of the galactose-6-sulfatase by
20% (as described in the earlier section)(Fig 3.29)
Figure 3.29.
In HT-1080 cells, galactose-6-sulfatase (Gal-6-S) and FGE-His or pFGE-His were stably
coexpressed. In the cell extracts, the expression of galactose-6-sulfatase, FGE-His
and pFGE-His was monitored by Western blotting using monoclonal antibodies against
galactose-6-sulfatase (lower panel) and the His tag (upper panel). The activity and specific
activity of galactose-6-sulfatase, referred to total cell protein and western blot signal of
Gal-6-S, respectively are shown at the bottom.
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3.2.6 Coelution of FGE-His and galactose-6-sulfatase
Through photocrosslinking experiment, we could demonstrate in vitro cross-linking
of purified FGE-His and photo labeled peptidic substrate (Fig 3.23, lane 5). There-
fore we were interested to check whether FGE and galactose-6-sulfatase form a
complex in vivo . This was done by passing the extracts of HT1080 cells coexpressing
FGE-His and galactose-6-sulfatase through gel filtration column. The result shows
that the complexes (270KDa) of FGE-His and galactose-6-sulfatase elute in fractions
13 to 16 (Fig 3.30. open square). The monomers of FGE-His (35KDa) elutes in
Figure 3.30. Coelution profile of galactose-6-sulfatase (Gal-6-S) and FGE-His
The extracts of HT1080 cells expressing FGE-His and galactose-6-sulfatase were fractionated
by Superdex-200 as described under ”Materials and Methods”. The fractions were analyzed
by immunobloting using a mixture of galactose-6-sulfatase and His-tag monoclonal antibodies.
Percentage of FGE-His or Gal-6-S were calculated by quantifying the western blot signals using
densitometry. In the graph, open square indicates that elution profile from cell expressing
galactose-6-sulfatase and FGE-His and closed square points, elution profile from cells expressing
either FGE-His or galactose-6-sulfatase alone.
fractions 18 to 21 and galactose-6-sulfatase elutes in fractions 16 to 21. In control
experiments, extracts from FGE-His or galactose-6sulfatase expressing HT1080 cells
were subjected to gel filtration chromatography. As can be seen from elution
pattern, galactose-6-sulfatase or FGE-His exclusively eluted as monomers in the
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same fractions where non-complexed fractions of FGE and Galactose-6-sulfatase
elute (Fig 3.30. closed square).
3.2.7 Co-immunoprecipitation of FGE-His and galactose-6-
sulfatase
The occurence of the FGE-His+galactose-6-sulfatase complex in vivo was evalu-
ated by immunoprecipitation of recombinant proteins. We observed specific co-
immunoprecipiation of FGE-His with galactose-6-sulfatase from lysates of HT1080
cells stably expressing FGE-His and galactose-6-sulfatase using FGE antiserum (Fig
3.31). The extracts of cells expressing only galactose-6-sulfatase was weakly precip-
itated by FGE antiserum, indicating that galactose-6-sulfatase forms complex with
endogenous FGE (Fig 3.31). However, we cannot exclude the possibility of complex
formation after extracting the cells.
Figure 3.31. Interaction of FGE-His and galactose-6-sulfatase
The HT1080 cell extracts of galactose-6-sulfatase and FGE-His or FGE-His or galactose-6-
sulfatase was subjected to immunoprecipitation with FGE antiserum. The presence of co-
precipitated galactose-6-sulfatase was detected by immunobloting with a monoclonal of antibody
against galactose-6-sulfatase. ∗ indicates the non specific detection from Staphylococcus aureus
cells which was used for immunoprecipitation
3.2.8 In vivo interaction between FGE-His and galactose-6-
sulfatase
Further, we investigated whether FGE-His forms complex with galactose-6-sulfatase
in vivo. To demonstrate this, cells stably expressing FGE-His and galactose-6-
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sulfatase were treated with the thio-cleavable chemical crosslinker dithiobis (succin-
imidyl propionate) (DSP). Cells were then lysed and the cell extracts were treated
with or without DTT to cleave DSP crosslinker. The extracts were resolved by SDS-
PAGE and FGE-His and galactose-6-sulfatse were identified by immunoblotting with
monoclonal antibodies against His-tag and galactose-6-sulfatase. The result reveals
that high molecular weight cross linked adduct (above 250 KDa) was detectable (Fig
3.32). This observation agrees with the 270KDa complex of FGE-His and galactose-
6-sulfatase which was shown by coelution experiment.
Figure 3.32. Chemical crosslinking of FGE-His and galactose-6-sulfatase
The HT1080 cells stably expressing FGE-His and galactose-6-sulfatase were treated with 2mM
DSP. Crosslinked proteins were treated with or without 50mM DTT, resolved on 15% SDS-PAGE.
After transferring into the nitrocellulose membrane, probed with either monoclonal antibodies
against His or galactose-6-sulfatase.
3.2.9 Retention of FGE in sulfatase expressing cells
FGE is localized in the endoplasmic reticulum. However it does not contain an
ER-retention signal of KDEL type. Its retention in the edoplasmic reticulum may
therefore be mediated by the interaction with other ER proteins. Upon stable
overexpression FGE escapes from the ER and is secreted. The time course of
intracellular accumulation and secretion of FGE-His by HT1080 cells showed that
a constant level of FGE is maintained in the cells and that the excess is secreted
(Fig 3.33, A). An intriguing result was observed when FGE-His and galactose-6-
sulfatase were stably coexpressed in HT1080 cells. Coexpression of galactose-6-
sulfatase dramatically reduced the secretion of FGE-His (Fig 3.33, B). Based on
these observations, we attempted to check whether overexpression of sulfatase
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Figure 3.33. Secretion of FGE-His
Fig.A, HT1080-cells stably expressing FGE-His were grown to half-confluency. At time 0, fresh
medium was added, and the cells were harvested after 12, 24, 36, and 48h of culture. FGE was
quantified in equal aliquots of cell extracts and media by western blotting using a monoclonal
antibody against His tag. The amount of intracellular and secreted FGE-His per mg of cell
protein was determined by calibration of the Western blot with known amounts of purified FGE-
His and referred to total cell protein. Fig.B, As described above, the secretion of FGE-His in
HT1080 cells overexpressing galactose-6-sulfatase and FGE-His was performed.
Figure 3.34. Secretion of pFGE-His
Fig.A, HT1080-cells stably expressing pFGE-His were grown to half-confluency. At time 0, fresh
medium was added, and the cells were harvested after 0, 12, 24, 36, and 48h of culture. pFGE
was quantified in equal aliquots of cell extracts (C) and media (M) by western blotting using a
monoclonal antibody against His tag. The amount of intracellular and secreted pFGE-His per
mg of cell protein was determined by calibration of the Western blot with known amounts of
purified pFGE-His and referred to total cell protein. Fig.B, As described above, the secretion of
pFGE-His in HT1080 cells overexpressing galactose-6-sulfatase and pFGE-His was performed
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impinge on the retention of pFGE. Coexpression of galactose-6-sulfatase did not
affect the secretion profile of pFGE-His ( Fig 3.34). This result supports the view that
the substrate mediated retention is specific for FGE and not shared by its paralogue.
Chapter 4
Discussion
The present study demonstrates that pFGE and FGE share many structural and
topological properties but differ functionally. FGE catalyzes the oxidation of a
cysteine residue, in the active site of sulfatases, to a FGly residue, whereas pFGE
lacks such an activity both in vitro and in vivo.
4.1 Molecular and cell biological characterization of
pFGE
Sequence searches revealed that SUMF2 encoded pFGE is found only in deuteros-
tomia, including vertebrates and echinodermata, and it shares 47% amino acid
identity and 62% similarity with SUMF1 encoded FGE [41]. Northern blot analysis
shows that pFGE is expressed ubiquitously in different tissues. Interestingly, we
found a comparable amount of SUMF2 messenger RNA with respect to the SUMF1
transcript in all the tissues analyzed with the highest level in pancreas and kidney
and the lowest in brain. The similar levels of SUMF1 and SUMF2 expression, point
to a function of pFGE that is related to FGE activity. Using real time PCR analysis,
Zito (2005) showed that SUMF2 expression in MSD cell lines was significantly
lower with respect to the controls, suggesting that the transcription of SUMF2 is
dependent on SUMF1.
The nucleotide sequence of pFGE predicts a N-terminal signal peptide, directing
translocation of the nascent polypeptide into the lumen of the enoplasmic reticulum.
HT1080 cells transiently expressing pFGE-HA were analyzed by immunofluores-
ence, where pFGE colocalized with PDI, an endoplasmic reticulum marker protein.
Interestingly in some over-expressing cells, pFGE was detected in the Golgi (Fig
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3.3, E). In contrast to recombinant pFGE, the endogenous pFGE was exclusively
localized in the endoplasmic reticulum. In addition, HT1080 cells stably over-
expressing pFGE-His were analyzed by immuno electron microscopy, where colo-
calization of pFGE-His with PDI or Glogi marker GM130 was detectable. pFGE-His
was also found in structures enriched in the endosomal /lysosomal marker LAMP1
(Fig 3.4). These data have to be further verified for endogenous pFGE in human
skin fibroblasts.
pFGE is localized in the lumen of the endoplasmic reticulum and it is found to be
a soluble glycoprotein. Nevertheless, a small fraction of endogenous protein escapes
from the endoplasmic reticulum into the secretions. Overexpression of pFGE-His in
HT1080 cells, results in its massive secretion. However, the cellular pFGE-His is
maintained at a constant level (Fig 3.5). pFGE is therefore likely to be retained
in the endoplasmic reticulum by a saturable mechanism. It should be noted that
pFGE lacks a canonical endoplasmic reticulum retention signal of the KDEL type.
It remains unclear how soluble resident proteins lacking this or a related motif
are retained in the endoplasmic reticulum. One possibility could be that pFGE
interacts with a KDEL type containing protein. Fishing of partners interacting
with immobilized pFGE was unsuccessful so far. It was recently demonstrated
that the C-terminal domain (57 residues) of Dictyostelium PDI lacking the HDEL
retrieval signal is necessary for endoplasmic reticulum retention [56]. Therefore it is
interesting to check whether the C-terminal region of pFGE confers the endoplasmic
reticulum retention. To our surprise, the secretion of FGE-His is markedly decreased
from cells coexpressing galactose-6-sulfatase and FGE-His (Fig 3.33), suggesting
that FGE retention may be mediated by their substrate sulfatases. Conversely,
coexpression of galactose-6-sulfatase has no impinge on secretion of pFGE-His (
Fig 3.34). This result suggests that pFGE may use a retention machinery which is
not shared by FGE.
pFGE has a single potential N-glycoyslation site at Asn 191. Full length pFGE
from cells and secretions differed in electrophoretic mobility by 0.5KDa (Fig 3.6).
The endoglycosidases experiment revealed that intracellular pFGE is sensitive to
Endo-H and PNGase F. Whereas, in two forms of secreted pFGE, the smaller form
is sensitive to Endo-H and the larger form is resistant. Both forms are sensitive
to PNGase F. MALDI-TOF analysis of tryptic glycopeptides of pFGE confirmed
heterogenous glycosylation at Asn 191. All these data suggest that during secretion,
the single high mannose type oligosaccharide of pFGE becomes processed to hybrid
and complex type structures containing fucose and sialic acid residues. Since for
4.1. Molecular and cell biological characterization of pFGE 81
intracellular pFGE only the high mannose type oligosaccharide was found, the
residence in the Golgi, as detected in some overexpressing cells (Fig 3.3, D-F), is
negligible. It is evident that Golgi-dependent modification reactions are restricted
to the fraction of pFGE that escapes endoplasmic reticulum retention and becomes
secreted. A similar result was observed when intra- and extracellular FGE were
digested with Endo-H or PNGase [54].
pFGE-His was purified from the secretions in a two step protocol on Ni-NTA
agarose followed by MonoQ anion exchange chromatography. On SDS gels and
Western blot, purified pFGE-His was detected in two molecular forms, the larger
with an apparent mass of 32.5 KDa and the smaller of 31.5 KDa. However,
both forms corresponded to full length pFGE with alanine 27 at its N-terminus.
The obvious explanation for this heterogeneity in size of secreted pFGE-His is its
different glycosylation pattern (Fig 3.6).
In order to detect endogenous and recombinant pFGE, we raised polyclonal
antibodies against purified pFGE-His in rabbit. Through immunoprecipitation ex-
periments, the polyclonal antibodies were shown to precipitate recombinant as well
as endogenous pFGE. In addition, it could be used to specifically detect pFGE in
immunofluoresence studies. Nevertheless, on Western blots pFGE antiserum weakly
cross-reacted with FGE.
After two attempts, we failed to produce polyclonal antiserum which could be
used to detect exclusively pFGE on Western blots. One explanation for this problem
could be that pFGE is too similar to FGE. On Western blots, FGE polypeptides are
largely denatured thereby all the epitopes were accessible to pFGE antiserum. To
avoid this problem, we raised monoclonal antibodies against purified pFGE-His
in mouse. All the hybridoma clones were screened by immunoprecipitation, im-
munoblotting and immunofluoresence experiments. Among many different clones,
the highly reactive clones were selected to produce ascites. Surprisingly, all these
monoclonal antibodies recognized His-tagged intracellular and secreted pFGE but
not untagged intracellular pFGE. Furthermore, they cross-reacted with His tagged
intracellular FGE and not with untagged intracellular and secreted FGE-His. These
observations were substantiated by immunofluoresence experiments. Taken to-
gether all these data support the conclusion that monoclonal antibodies were likely
raised against epitopes that includes the His-tag of pFGE-His.
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Phylogenetic sequence comparison revealed that pFGE and FGE contain three
highly conserved regions. In pFGE, these subdomains make up more than 85%
of the molecule. Digestion with either elastase, a serine protease, or thermolysin,
a zinc-metalloproteinase, generated two stable fragments by proteolytic cleavage
within the short linker sequence connecting the first and the second subdomain.
This suggested that the three conserved regions correspond to folding domains.
In collaboration with Achim Dickmanns, the crystal structure of pFGE was deter-
mined , which represents the first three dimensional structure of a DUF323 domain
[57]. In contrast to the domain mapping studies, the pFGE structure revealed a
single domain of a novel fold with a strikingly low degree of secondary structure.
pFGE structure was used to determine the crystal structure of FGE, revealing a
high structural similarity [58](Fig 4.1)). FGE contains three highly conserved
Cell
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Figure 2. Comparison of FGE and pFGE
(A) Superposition of FGE and pFGE. pFGE is
shown as a gray ribbon representation,
whereas for FGE α helices are colored red, β
strands blue, and loop regions yellow. The
two Ca2+ ions in pFGE are drawn in gray, and
the Ca2+ ions in FGE are shown as transpar-
ent spheres in cyan (site 1) and magenta (site
2). The three insert regions in FGE relative to
pFGE are labeled and shown in green. The
carbohydrate moieties are located on oppo-
site sides of the molecules and are drawn as
stick models.
(B) Stereochemistry of Ca2+ binding site 2 in
pFGE (left) and FGE (right). The side chain of
pFGE Leu230 is truncated at Cβ for clarity.
(C) Effect of the absence of the second disul-
fide bond in pFGE (left) compared to FGE
(right). The σA-weighted mFo − DFc omit
electron density map around the disulfide
bond is contoured at 3σ.
Ca2+ by analysis of their coordination sphere and by the presence of a new ligand, Glu130, instead of the
Pro68 present in pFGE. The Glu130 side chain replacesanomalous difference Fourier maps calculated from a
data set of high multiplicity (not shown). In addition, the the water molecule and shifts the Ca2+ ion by 0.85 Å
relative to its position in pFGE. This abolishes the in-crystallization conditions included >0.2 M CaCl2, ensur-
ing full occupancy of the Ca2+ sites. Although K+ is an- teraction with the carbonyl group of Leu230, and a
water molecule occupies the free coordination site. Theother candidate ion for the observed binding geome-
tries and the Fourier analyses, given the much higher net result is an almost perfect octahedral coordination
of Ca2+ in FGE by the side chains of Glu130 and Glu300,concentration of Ca2+ compared to K+ in the ER, any
significant binding of K+ to FGE in vivo seems unlikely, the carbonyl groups of Asn293, Gly296, and Ala298,
and a water molecule (Figure 2B, right). As Glu130 isand Ca2+ will be the natural ligand for FGE. This conclu-
sion is also supported by plasma mass spectroscopic conserved in all FGE sequences and, likewise, Pro68 is
conserved in all pFGE sequences, it can be concludedresults (see below). Two similarly located Ca2+ ions
have been identified in pFGE (Dickmanns et al., 2005), that the Ca2+ geometry at site 2 will be the same for all
FGEs and pFGEs and exhibit the same differenceswhich is also retained in the ER. The Ca2+ ion at site 1
in FGE is 7-fold coordinated by a bidentate interaction when FGEs and pFGEs are compared. In summary, the
Ca2+-coordinating residues are conserved in most FGEwith the Asp273 side chain, the Asn259 side chain, the
carbonyl groups of Ile260 and Phe275, and two water sequences, suggesting that the two Ca2+ ions are an
integral part of FGE/pFGE protein stability.molecules. The coordination geometry can best be de-
scribed as a distorted pentagonal bipyramid and is The observation that pFGE crystallizes as a dimer in
the asymmetric unit (Dickmanns et al., 2005) and, moreconserved in pFGE. In pFGE, Ca2+ site 2 is coordinated
in an irregular fashion by the side chain of Glu236, the compellingly, that FGE/pFGE expression levels are sim-
ilar throughout different tissue types and that pFGEcarbonyl groups of Asp229, Leu230, Gly232, and
Val234, and one water molecule (Figure 2B, left). This overproduction antagonizes FGE activity (Mariappan et
al., 2005) suggests the possibility that FGE may formion binding site differs drastically in FGE because of
Figure 4.1. Comparison of FGE and pFGE (Dierks et., al 2005)
Superposition of FGE and pFGE. pFGE is shown as a gray ribbon representation, whereas for
FGE α helices are colored red, β strands blue, and loop regions yellow. The two Ca2+ ions in
pFGE are drawn in gray, and the Ca2+ ions in FGE are shown as transparent spheres in cyan
(site 1) and magenta (site 2). The three insert regions in FGE relative to pFGE are labeled and
shown in green. The carbohydrate moieties are located on opposite sides of the molecules and
are drawn as stick models.
cysteine residues in the highly conserved C-terminal region (subdomain III [54]).
Two of them have been shown to be critical for its catalytic activity [58]. Both
4.1. Molecular and cell biological characterization of pFGE 83
these cysteines are missing in pFGE. pFGE contains two cysteine residues located
in subdomain II (Cys156) and another in subdomain III (C290). They form an
intra- molecular disulfide bond linking subdomains II and III. This disulfide bond is
conserved in FGE, in which two inter subdomain disulfide bridges link subdomains
II and III [54]. Therefore, in pFGE as well as in FGE, subdomains II and III are
tightly connected and together form a large protease-resistant domain.
4.1.1 Functional properties of pFGE
The localization, carbohydrate processing and secretion upon overexpression as
well as protease sensitivity of the linker region between the first two subdomains
are properties that FGE shares with its paralog FGE [54]. Moreover, the rela-
tive abundance of their mRNAs in different tissues is rather similar. All these
observations suggest that pFGE and FGE fulfill similar functions. A known and
important functional property of FGE is its FGly generating activity, an essential
protein modification for sulfatases that renders them catalytically active. The critical
role of FGE for the FGly formation is evident from the loss of catalytically active FGly
containing sulfatases in MSD patients that carry mutations in the gene encoding
FGE [51, 41]. Cells of these patients accumulate catalytically inactive sulfatases
that retain the cysteine residue, which normally is oxidized by FGE to FGly [18].
So far, no mutations in the pFGE-encoding SUMF2 gene have been found in MSD
patients.
Under conditions appropriate for the FGly-generating activity of FGE towards
peptidic substrates, pFGE was inactive (Fig 3.20,Table 3.1). This was true for the
peptides derived from the 16 sulfatases known or predicted from the human genome
sequence. Thus, under in vitro conditions, pFGE lacks FGly-generating activity. This
result agrees with crystallographic studies of pFGE and FGE showing that pFGE
lacks the redox-active Cys 336 of FGE [58]. The increase of sulfatase activity upon
coexpression of pFGE with sulfatases as observed by Cosma et al., (2003), had
suggested that in vivo pFGE has FGly-generating activity or is stimulating the activity
of endogenous FGE . We failed to observe an increase of sulfatase activity upon
transient or stable coexpression of pFGE.
Surprisingly, in HT-1080 cells, the coexpression of pFGE decreased rather than
increasing the activity of coexpressed sulfatases (Fig 3.21). In an attempt to
understand this inhibitory effect, we examined the interaction of pFGE with sul-
fatases and FGE. We could demonstrate the interaction of an ASA fragment and
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short ASA-derived peptides with pFGE in a yeast two hybrid approach and by
photocrosslinking, respectively. The possibility of interaction between pFGE and
ASA derived peptides could be explained at molecular level by crystallographic
studies. Many of the residues (Ala149, Ser155, Trp299, Ser356, Asn360, and
Leu361) lining the substrate binding groove in FGE are conserved in pFGE. This
points to the possibility that pFGE competes with FGE for substrates [58]. Pro-182
of FGE, which was shown to chemically cross-link with the bound substrate related
peptide, is structurally conserved in pFGE (Pro-120). These prolines border one end
of a cleft thought to be involved in peptide binding [57](Fig4.2).
Figure 4.2. Comparison of the putative peptide binding clefts of pFGE and FGE (Achim et.,
al 2005)
A, left, pFGE in gray with the cleft (yellow) most likely to be involved in the binding of the
sulfatase polypeptide chain colored in yellow. Pro-120, colored in blue, corresponds to Pro-182
of FGE that has been shown to cross-link to a substrate peptide. Right, the FGE cleft is shown
in the same color code used for pFGE. The amino acid changes are highlighted in red and are
predominantly located in the region of the putative reaction center.
In yeast two hybrid assay, we could also observe an interaction between pFGE
and FGE. It was shown that the first two cysteine residues in FGE are involved in
the formation of homodimer [54]. Therefore, we were keen to check whether pFGE
makes intermolecular disulfide with FGE. In cells expressing FGE and pFGE treated
with NEM prior to harvesting, no heterodimer of pFGE and FGE was detected on
Western blots of non reducing SDS-gels. Furthermore, we were unable to detect a
thiol mediated homodimer of pFGE from cells over-expressing pFGE. Nevertheless,
pFGE was crystallized as a homodimer in the asymmetric unit [57]. This observation
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suggests that homodimer formation of pFGE might implicate to its function. Further,
we have to verify the possibility of homodimer formation of pFGE through non
covalent interactions by using differentially tagged pFGE molecules.
We also analysed whether pFGE forms a direct physical interaction with FGE. Ni-
agarose pull down assay, gel permeation chromatography and cross-linking were
performed, employing extracts of pFGE-His and FGE coexpressing cells. Yet, we
failed to detect complexes of pFGE and FGE. In solution, no heterodimers of purified
pFGE and FGE were observed by gel permeation chromatography, suggesting that
the affinity of pFGE for FGE, if present, is low. pFGE/FGE dimers are sterically
possible, albeit with a small buried surface area and low surface complementarity
[57]. In order to rule out the possibility of His tag interfering the interaction of
pFGE and FGE, we made coimmunoprecipitation experiments using cells expressing
untagged pFGE and FGE. The results clearly state that no complexes of pFGE
and FGE were precipitated (Fig 3.25). However, Zito et al., (2005) described,
the complexes of pFGE and FGE detected by coimmunoprecipiation experiments
[59]. The contradictory results between our two groups remain to be resolved and
theoretically can be due to the cell lines which were used for co-expression of pFGE
and FGE.
Apparently, the interaction of pFGE and FGE as observed on the yeast two hybrid
experiments could not be confirmed by biochemical approaches. Albeit, we cannot
exclude that pFGE and FGE interaction could be substrate-dependent. In solution,
heterodimers of pFGE and FGE in the presence of peptidic substrates were not
detected by gel permeation chromatography. This observation was substantiated
by cross linking experiments with a mixture of pFGE, FGE and substrate peptide.
Further, we checked this interaction by using cells expressing pFGE, FGE and
arylsulfatase A. Consistently, we found that neither pFGE nor FGE antiserum could
precipitate complexes of pFGE and FGE.
4.1.2 Which is the biological role of pFGE?
Taken together, our results support the view that pFGE lacks FGly-generating
activity. Thus, we may conclude that pFGE is not responsible for the residual
activity of sulfatases in MSD patients [41]. Nevertheless the function of pFGE is
likely to be related to FGE funtion for seven reasons.
1. The SUMF2 expression levels are substantial though absolutely variable and the
relative pFGE/FGE ratios are approximately equal in all tissue types studied.
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2. In MSD cells, SUMF2 expression was significantly lower with respect to the
controls, suggesting that the transcription of SUMF2 is dependent on SUMF1[59].
3. pFGE and FGE are colocalized in the endoplasmic reticulum.
4. Recently pFGE/FGE heterodimerization has been observed by coimmunopre-
cipitation of the proteins from transfected Cos7 cells [59]. In addition, this study
reported a trimolecular complex of pFGE, FGE, and sulfatases.
5. The compromising effect of pFGE on FGE mediated generation of catalytically
active sulfatases in coexpression studies
6. pFGE has been shown to bind peptides bearing the recognition motif required
for the generation of FGly in arylsulfatase A in vitro.
7. The three dimensional structures of pFGE and FGE are closely related and share
residues bearing the peptide binding groove [57, 58].
A number of proposals can be suggested to explain the role of pFGE. In vivo the
overexpression of pFGE interferes with the FGly formation in sulfatases indicated
by the decrease of sulfatase activity without concomitant decrease in sulfatase
polypeptide. This effect may be due to binding of sulfatases to pFGE thereby
sequestrating them from FGE. In vitro, addition of pFGE to a mixture of FGE and
its peptidic substrate P23 has no effect on the FGly formation. While this result
suggests an effect of pFGE on FGE activity in vivo, it can be expected that another
unidentified protein with a function that links pFGE to FGE activity may be induced.
The effects of pFGE on FGE are also conceivable either in a indirect manner, e.g., by
dislocating FGE from the endoplasmic reticulum due to competition for a common
retention mechanism, or directly by heterodimerization. The earlier possibility is
not likely to happen because the retention of FGE appears to be mediated by the
sulfatase substrates, which is not true for pFGE. The latter possibility is so far
not confirmed by biochemical approaches but agrees with the crystal structure of
pFGE which shares structural similarity with FGE. Moreover, the formation of a
heterodimer appears to be stereochemically possible [57]. It is plausible, that pFGE
may act as a modulator of FGE activity. Thus, pFGE may control the amount of
the FGly activated sulfatases to be synthesised. Further, it will be fascinating to
determine whether pFGE regulation is sulfatase specific and/ or tissue specific. To
identify the precise biological role of pFGE, the detailed analysis of the molecular
interaction of pFGE and FGE and nascent sulfatase polypeptides as well as ablation
of pFGE are required. Soon pFGE knock-out mice will be available, which hopefully
will help to elucidate the precise role that pFGE plays on sulfatase activation.
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4.2 FGE as a tool to improve the production of re-
combinant sulfatases
Inactivity of FGE causes multiple sulfatase deficiency (MSD), an autosomal recessive
lysosomal storage disease. In sulfatases, FGE posttranslationally converts a cysteine
residue to FGly, which is part of the catalytic site and is essential for sulfatases
activity. Overexpression of sulfatases can be associated with a decrease of the ac-
tivity of endogenous sulfatases [52]. Furthermore, the endogenous FGE is limiting
the synthesis of active recombinant sulfatases. The recent preclinical studies from
Matzner et al., (2005) in a mouse model of metachromatic leukodystrophy (MLD)
revealed that intravenous injection of the human recombinant ASA can reduce
excess sulfatide in peripheral nervous system and kidney by up to 70%. They
also demonstrate the passage of lysosomal enzymes through the blood brain barrier
and their delivery to the brain. These studies encourage the enzyme replacement
therapy for single sulfatases deficiency. In order to produce catalytically active
sulfatases, we began to examine the effect of FGE on sulfatases. Our findings
show that FGE is absolutely necessary for the expression of catalytically active
recombinant sulfatases. Thus, these studies have profound implications for the mass
production of active sulfatases to be utilized for enzyme replacement therapy.
4.2.1 Concurrent expression of FGE and sulfatase is essential to
produce highly active sulfatase
When FGE-HA and steroid sulfatase (STS) were coexpressed in HT1080 or HT1080-
galactose-6-sulfatase cells, STS activity increased in both the cells, but the increase
was more pronounced in HT1080-galactose-6-sulfatase. The variable results be-
tween the two cell lines could be explained. In HT1080 cells, the endogenous FGE
is able to modify recombinant STS to some extent, thus, we could not see a distinct
effect of FGE on STS. But, in HT1080-galactose-6-sulfatse cells, the superfluous
expression of galactose-6-sulfatase by far exceeded the FGly generating capacity of
endogenous FGE, thus leaving large amounts of unmodified galactose-6-sulfatase
and STS as substrates for recombinant FGE.
Strikingly, the specific activity of galactose-6-sulfatase increased more than 100
fold in HT1080 cells stably coexpressing FGE-His and galactose-6-sulfatase. Con-
versely, we failed to notice a significant difference of Gal-6-S activity when we
transiently transfected FGE-His into HT1080-galactose-6-sulfatase cells. The dis-
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crepancy between the two experiments can be explained. In transient transfection
FGE-His does not reach all cells and so concomitant. But, in the stable cell line,
the synthesis of FGE-His and galactose-6-sulfatase is concomitant, hence FGE-
His could modify almost all newly synthesized galactose-6-sulfatase. However, it
is unclear whether all the galactose-6-sulfatases are catalytically active in these
cells. One potential way to address this question is to quantify the FGly content
in galactose-6-sulfatase. Takakusaki et al., (2005) also examined the validity of
FGE coexpression for the expression of a catalytically active ASA enzyme, as a step
in the development of gene therapy for metachromatic leukodystrophy (MLD). In
addition this study reported that FGE coexpression did not affect ASA mRNA or
protein levels and half life of ASA. Synergistic activation was clearly demonstrated
in their in vivo experiments. Simultaneous injection of ASA cDNA with FGE cDNA
by a hydrodynamic procedure significantly increased ASA activity in the liver and
serum of ASA deficient (MLD) mice. However, they could not show the transfer of
ASA protein from blood to the brain.
4.2.2 Formation of FGE-sulfatase complexes in the ER: retention
mechanism or non-productive complexes?
FGE-His can be crosslinked with photolabelled substrate (Fig 3.23, lane 1). A
yeast two hybrid assay revealed that ASA fragment harboring FGly modification
motif interacts with FGE [54]. These data tempted us to check whether FGE and
sulfatases form a complex in vivo . When extract of HT1080 cells coexpressing FGE-
His and galactose-6-sulfatase were subjected to gel permeation chromatography,
complexes of FGE and galactose-6-sulfatase coeluted (Fig 3.30). The apparent
size of the FGE-His and galactose-6-sulfatase complex was 270 KDa. However,
FGE-His and galactose-6-sulfatase partially eluted as monomers of 35 KDa and
55 KDa, respectively. The complex formation must be specific because pFGE-His
and galactose-6-sulfatase did not colelute when passing the cell extracts of pFGE-
His and galactose-6-sulfatase on gel permeation chromatography (Fig 3.24). The
stoichiometry of this complex is yet to be characterized.
Further, we verified the interaction of FGE-His and galactose-6-sulfatase by coim-
munoprecipitation. Again, we found that FGE-His coprecipitated with galactose-
6-sulfatase (Fig 3.31). However, we cannot exclude that the complex formation
might occur after extracting the cells. To exclude the later possibility, we have done
in vivo chemical cross-linking of FGE-His and galactose-6-sulfatase. In agreement
with the coelution experiment, we could observe the high molecular weight cross
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linked adduct (above 250 KDa). To substantiate these data, we should repeat these
studies with different sulfatases coexpressed with FGE.
It is unclear whether the complex comprises only FGE-His and galactose-6-
sulfatase or some unknown factor. This can be achieved by purifying the complex
and analysing by MALDI-TOF. Further, it will be interesting to know whether
FGE forms complexes with catalytically active or inactive galactose-6-sulfatase or
whether inactive complexes are eventually converted into active complexes allowing
for quantitative FGly-modification. The later is suggested by the observation that
the specific activity of galactose-6-sulfatase increased up-to 100 fold in these cells. It
has been shown that FGE can not modify completely folded and inactive sulfatases
because the FGly motif is buried inside the sulfatases. To exclude whether the
complex formation occurs through non specific interactions, one has to coexpress
FGE-His with mutated galactose-6-sulfatase (Cys79Ser) and to analyze for the
complex formation. Further it will be intriguing to understand the physiological
role of FGE-sulfatase complexes and what is limiting the release of non-complexed
sulfatase.
Recombinant and endogenous FGE are localized in the endoplasmic reticulum
[41, 54]. But, FGE by-itself does not contain a canonical endoplasmic reticulum
retention signal. The retention mechanism of FGE in the endoplasmic reticulum
remains elusive. Upon stable overexpression, FGE escapes from the endoplasmic
reticulum and is secreted (Fig 3.33, A). However, the intracellular FGE was kept at
a constant level. When we stably coexpressed FGE-His and galactose-6-sulfatase
in HT1080 cells, the secretion of FGE-His was dramatically reduced (Fig 3.33,
B). In parallel, we repeated this experiment with cells coexpressing pFGE-His and
galactose-6-sulfatase, where coexpression of galactose-6-sulfatase did not have an
influence on secretion of pFGE-His ( Fig 3.34). This result supports that sulfatase-
mediated retention of FGE is specific for FGE and not shared by its paralogue. In
order to certify these observations, we should repeat this experiment with different
sulfatases coexpressing with FGE. These findings lead us to propose that FGE is
constantly interacting and modifying all the newly synthesized nascent sulfatase
polypeptides and thus it is retained in the endoplasmic reticulum. In order to
confirm this observation, we should repeat these secretion studies with different
sulfatases coexpressed with FGE.

Summary
Cα-formylglycine (FGly) is the catalytic residue in the active site of sulfatases.
In eukaryotes, it is generated in the endoplasmic reticulum by post-translational
modification of a conserved cysteine residue. The enzymatic activity of sulfatases
depends on this posttranslational modification which is mediated by a recently
identified unique enzyme named as formylglycine generating enzyme (FGE). The
genetic defect of FGE causes multiple sulfatase deficiency (MSD), a lysosomal
storage disorder. In the genomes of deuterostomia, including vertebrates and
echinodermata, a paralog of FGE, designated as pFGE, is exist. The human pFGE
shares 47.1% sequence identity and 62.1% similarity with human FGE. The function
of the pFGE is unknown. The goal of this study was to identify and analyze
the structural and functional properties of pFGE. In comparison with FGE, pFGE
shares a tissue specific expression pattern and the localization in the lumen of the
endoplasmic reticulum. Upon overexpression, both FGE and pFGE escape from the
endoplasmic reticulum and get secreted. However a constant level of pFGE or FGE is
maintained in the cells. Although both lack endoplasmic reticulum retention signal,
they are still retained by an unknown saturable mechanism. pFGE was purified to
homogeneity from the secretions in a two-step protocol on Ni-NTA agarose followed
by anion exchange chromatography and polyclonal and monoclonal antibodies were
raised. Limited proteolytic cleavage at similar sites indicates that both also share a
similar three-dimensional structure. pFGE, however, is lacking the formylglycine-
generating activity of FGE towards peptidic substrates. This observation holds true
for peptidic substrates derived from all 16 sulfatases known or predicted from
the human genome. Although overexpression of FGE stimulates the generation
of catalytically active sulfatases, overexpression of pFGE has an inhibitory effect. In
vitro pFGE interacts with sulfatase-derived peptides but not with FGE. The inhibitory
effect of pFGE on the generation of active sulfatases may therefore be caused by a
competition of pFGE and FGE for newly synthesized sulfatase polypeptides.
In an independent study, we examined the utility of FGE for overexpression of
catalytically active sulfatases in a way to improve the efficacy of sulfatase replace-
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ment therapy. Our data demonstrating that FGE coexpression is indispensable for
efficient synthesis of functional sulfatases. HT1080 cells were stably transfected
with galactose-6-sulfatase and FGE. The specific activity of galactose-6-sulfatase
increased up to 100 fold in cell lysates by coexpression of FGE. Interestingly,
stimulation of sulfatase activity is more pronounced when FGE and sulfatase are
concomitantly expressed in the HT1080 cells. Moreover, stable FGE-sulfatase com-
plexes are formed in the endoplasmic reticulum but its physiological significance
remains elusive. However, this complex formation may aid in the retention of FGE
as a substrate-mediated phenomenon; substantiated by the observation that the
secretion of FGE is reduced markedly when coexpressed with sulfatase.
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